UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June~~September 30, 2023


☐	TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

From the transition period from to

Commission File Number 001-37853

FIRST WAVE BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware

46-4993860

(State or other jurisdiction of

incorporation or organization)

(I.R.S Employer

Identification No.)

777 Yamato Road, Suite 502

Boca Raton, Florida 33431

(Address of principal executive offices) (Zip Code)

(561) 589-7020

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common stock, par value $0.0001 per share	FWBI	The Nasdaq ~~Capital~~Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

There were ~~7,152,204~~13,499,979 shares of the registrant’s common stock, par value $0.0001 per share (the “Common Stock”), outstanding as of ~~August~~November 10, 2023.

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (“Quarterly Report”) contains forward-looking statements that involve substantial risks and uncertainties. All statements contained in this Quarterly Report other than statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

The words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “target”, “potential”, “will”, “would”, “could”, “should”, “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about:

●

our ability to regain and maintain compliance with the continued listing requirements of The Nasdaq Stock Market LLC;

●

our ability to satisfy our payment obligations under the First Wave Acquisition (as defined below);

●

statements regarding the impact of the COVID-19 pandemic and other geopolitical events, including the wars in Israel and Ukraine and their effects on our operations, access to capital, research and development and clinical trials and potential disruption in the operations and business of third-party vendors, contract research organizations (“CROs”), contract development and manufacturing organizations (“CDMOs”), other service providers, and collaborators with whom we conduct business;

●

the availability of capital to satisfy our working capital requirements;

●

our current and future capital requirements and our ability to raise additional funds to satisfy our capital needs;

●

the integration and effects of our acquisitions and other strategic transactions;

●

the accuracy of our estimates regarding expense, future revenue and capital requirements;

●

our ability to continue operating as a going concern;

●

our plans to develop and commercialize our product candidates, including Capeserod, the biologic Adrulipase and Niclosamide;

●

our ability to initiate and complete our clinical trials and to advance our principal product candidates into additional clinical trials, including pivotal clinical trials, and successfully complete such clinical trials;

●

regulatory developments in the U.S. and foreign countries;

●

the performance of our third-party vendor(s), CROs, CDMOs and other third-party non-clinical and clinical development collaborators and regulatory service providers;

●

our ability to obtain and maintain intellectual property protection for our core assets;

●

the size of the potential markets for our product candidates and our ability to serve those markets;

●

the rate and degree of market acceptance of our product candidates for any indication once approved;

●

the success of competing products and product candidates in development by others that become available for the indications that we are pursuing;

-1-

Table of Contents

●

the loss of key scientific, clinical and nonclinical development, and/or management personnel, internally or from one of our third-party collaborators; and

●

other risks and uncertainties, including those listed under Part I, Item 1A., “Risk Factors” in our Annual Report on Form 10-K.

Factors that may cause actual results to differ materially from current expectations include, among other things, those set forth in Part I, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K and for the reasons described elsewhere in this Quarterly Report on Form 10-Q. Any forward-looking statement in this Quarterly Report on Form 10-Q reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given these uncertainties, you should not rely on these forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, our business and the markets for certain drugs and consumer products, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources and we have not independently verified the data from third party sources. In some cases, we do not expressly refer to the sources from which these data are derived.

In this Quarterly Report on Form 10-Q, unless otherwise stated or as the context otherwise requires, references to “First Wave,” the “Company,” “we,” “us,” “our” and similar references are to First Wave BioPharma, Inc. and its subsidiaries on a consolidated basis. References to “First Wave BioPharma” refer to First Wave BioPharma, Inc. on an unconsolidated basis. References to “AzurRx SAS” refer to AzurRx SAS, First Wave BioPharma’s former wholly-owned subsidiary through which we conducted our European operations, which was dissolved effective October 26, 2022. References to “FWB” refer to First Wave Bio, Inc., First Wave BioPharma’s wholly-owned subsidiary.

-2-

Table of Contents

PART I

FINANCIAL INFORMATION

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to present fairly our financial position, results of operations, and cash flows for the interim periods presented. We have consolidated such financial statements in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). Therefore, such financial statements do not include all disclosures required by accounting principles generally accepted in the United States of America. In preparing these unaudited condensed consolidated financial statements, the Company ~~(as defined below)~~ has evaluated events and transactions for potential recognition or disclosure through the date the unaudited condensed consolidated financial statements were issued by filing with the SEC.

These financial statements should be read in conjunction with our audited financial statements for the year ended December 31, 2022 included in our Annual Report filed on Form 10-K, filed with the SEC on March 20, 2023.

The results of operations for the three and ~~six~~nine months ended ~~June~~September 30, 2023 are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2023.

~~-1-~~-3-

Table of Contents

FIRST WAVE BIOPHARMA, INC.

Condensed Consolidated Balance Sheets

June 30,

2023

December 31,

(unaudited)

2022
ASSETS

Current Assets:

Cash and cash equivalents

$
1,236,054

$
1,362,910
Other receivables

—

93,014
Prepaid expenses

1,117,737

1,956,831
Total Current Assets

2,353,791

3,412,755

Property, equipment, and leasehold improvements, net

29,202

43,839

Other Assets:

Restricted cash

21,519

21,513
Goodwill

1,684,182

1,684,182
Operating lease right-of-use assets

227,927

259,261
Deposits

11,250

18,149
Total other assets

1,944,878

1,983,105
Total Assets

$
4,327,871

$
5,439,699

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:

Accounts payable

$
1,591,195

$
720,040
Accrued expenses

479,862

320,176
Accrued dividend payable

943,243

761,488
Note payable

153,478

603,494
Operating lease liabilities

63,564

66,151
Other current liabilities

29,907

12,138
Total Current Liabilities

3,261,249

2,483,487
Non-current operating lease liabilities

184,662

214,060
Total Liabilities

3,445,911

2,697,547

Stockholders’ Equity:

Common Stock - Par value $0.0001 per share; 50,000,000 shares authorized; 4,208,995 and 995,003 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively

421

100
Series B preferred stock- Par value $0.0001 per share; 5,194.81 shares designated; 545.94 and 550.17 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively

—

—
Series C preferred stock- Par value $0.0001 per share; 75,000 shares designated; 0 shares issued and outstanding at June 30, 2023 and December 31, 2022

—

—
Series D preferred stock- Par value $0.0001 per share; 150 shares designated; 0 shares issued and outstanding at June 30, 2023 and December 31, 2022

—

—
Series E preferred stock- Par value $0.0001 per share; 150 shares designated; 0 shares issued and outstanding at June 30, 2023 and December 31, 2023

—

—
Series F preferred stock- Par value $0.0001 per share; 7,000 shares designated; 0 shares issued and outstanding at June 30, 2023 and December 31, 2023

—

—
Additional paid-in capital

177,675,113

171,275,741
Accumulated deficit

(176,793,574)

(168,533,689)
Total Stockholders’ Equity

881,960

2,742,152
Total Liabilities and Stockholders’ Equity

$
4,327,871

$
5,439,699


	September 30,
	2023		December 31,
	(unaudited)		2022
ASSETS

Current Assets:
Cash and cash equivalents	$	3,292,327	$	1,362,910
Other receivables		—		93,014
Prepaid expenses		684,273		1,956,831
Total Current Assets		3,976,600		3,412,755

Property, equipment, and leasehold improvements, net		21,884		43,839

Other Assets:
Goodwill		1,684,182		1,684,182
Restricted cash		21,521		21,513
Operating lease right-of-use assets		211,832		259,261
Deposits		11,250		18,149
Total Other Assets		1,928,785		1,983,105
Total Assets	$	5,927,269	$	5,439,699

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:
Accounts payable	$	579,291	$	720,040
Accrued expenses		834,540		320,176
Accrued dividend payable		992,535		761,488
Note payable		—		603,494
Operating lease liabilities		65,322		66,151
Other current liabilities		10,806		12,138
Total Current Liabilities		2,482,494		2,483,487

Non-current operating lease liabilities		165,970		214,060
Total Liabilities		2,648,464		2,697,547


Stockholders’ Equity:
Common stock - Par value $0.0001 per share; 50,000,000 shares authorized; 13,463,479 and 995,003 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively		1,346		100
Series B preferred stock- Par value $0.0001 per share; 5,194.81 shares designated; 521.72 and 550.17 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively		—		—
Series C preferred stock- Par value $0.0001 per share; 75,000 shares designated; 0 shares issued and outstanding at September 30, 2023 and December 31, 2022		—		—
Series D preferred stock- Par value $0.0001 per share; 150 shares designated; 0 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively		—		—
Series E preferred stock- Par value $0.0001 per share; 150 shares designated; 0 shares issued and outstanding at September 30, 2023 and December 31, 2022		—		—
Series F preferred stock- Par value $0.0001 per share; 7,000 shares designated; 0 shares issued and outstanding at September 30, 2023 and December 31, 2022		—		—
Additional paid-in capital		183,505,191		171,275,741
Accumulated deficit		(180,227,732)		(168,533,689)
Total Stockholders’ Equity		3,278,805		2,742,152
Total Liabilities and Stockholders’ Equity	$	5,927,269	$	5,439,699

See accompanying notes to unaudited condensed consolidated financial statements

~~-2-~~-4-

Table of Contents

FIRST WAVE BIOPHARMA, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2023

2022

2023

2022
Operating expenses:

Research and development expenses

$
1,353,095

$
2,906,896

$
2,714,778

$
7,883,413
General and administrative expenses

2,828,549

2,498,957

5,529,291

6,904,512
Total operating expenses

4,181,644

5,405,853

8,244,069

14,787,925

Loss from operations

(4,181,644)

(5,405,853)

(8,244,069)

(14,787,925)

Other (expenses) income:

Interest expense

(5,178)

(3,218)

(14,165)

(8,823)
Interest income

205

926

2,078

1,065
Other expense

(2,615)

—

(3,729)

(239,301)
Total other expenses

(7,588)

(2,292)

(15,816)

(247,059)

Net loss

$
(4,189,232)

$
(5,408,145)

$
(8,259,885)

$
(15,034,984)

Other comprehensive loss:

Foreign currency translation adjustment

—

(136,946)

—

(195,351)
Total comprehensive loss

$
(4,189,232)

$
(5,545,091)

$
(8,259,885)

$
(15,230,335)

Net loss

$
(4,189,232)

$
(5,408,145)

$
(8,259,885)

$
(15,034,984)
Deemed dividend on warrant modifications

—

(47,300)

—

(47,300)
Preferred stock dividends

(94,324)

(97,125)

(181,755)

(187,917)
Net loss applicable to common shareholders

$
(4,283,556)

$
(5,552,570)

$
(8,441,640)

$
(15,270,201)

Basic and diluted weighted average shares outstanding

2,270,922

103,844

2,725,755

89,015
Loss per share - basic and diluted

$
(1.89)

$
(53.47)

$
(3.10)

$
(171.55)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Operating expenses:
Research and development expenses	$	1,011,055	$	791,067	$	3,725,833	$	8,674,480
Research and development recovery - intellectual property acquired		—		(8,085,045)		—		(8,085,045)
General and administrative expenses		2,422,082		2,904,448		7,951,373		9,808,960
Total operating expenses (recovery)		3,433,137		(4,389,530)		11,677,206		10,398,395

(Loss) income from operations		(3,433,137)		4,389,530		(11,677,206)		(10,398,395)

Other (expenses) income:
Interest expense		(1,250)		(863)		(15,415)		(9,686)
Interest income		229		2,664		2,307		3,729
Other expense		—		—		(3,729)		(239,301)
Total other (expenses) income		(1,021)		1,801		(16,837)		(245,258)

Net (loss) income	$	(3,434,158)	$	4,391,331	$	(11,694,043)	$	(10,643,653)

Other comprehensive (loss) income:
Foreign currency translation adjustment		—		(35,235)		—		(230,586)
Total comprehensive (loss) income	$	(3,434,158)	$	4,356,096	$	(11,694,043)	$	(10,874,239)

Net (loss) income	$	(3,434,158)	$	4,391,331	$	(11,694,043)	$	(10,643,653)
Deemed dividend on warrant modifications		—		(47,300)		—		(47,300)
Preferred stock dividends		(49,292)		(110,278)		(231,047)		(298,195)
Net (loss) income applicable to common shareholders	$	(3,483,450)	$	4,233,753	$	(11,925,090)	$	(10,989,148)

Basic weighted average shares outstanding		7,566,018		228,773		3,763,506		136,113
Diluted weighted average shares outstanding		7,566,018		232,248		3,763,506		136,113
Net (loss) income per share – basic	$	(0.46)	$	18.51	$	(3.17)	$	(80.74)
Net (loss) income per share – diluted	$	(0.46)	$	18.23	$	(3.17)	$	(80.74)

See accompanying notes to unaudited condensed consolidated financial statements

~~-3-~~-5-

Table of Contents

FIRST WAVE BIOPHARMA, INC.

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) (unaudited)

Series B Convertible

Additional

Total

Preferred Stock

Common Stock

Paid In

Accumulated

Stockholders’


Shares

Amount

Shares

Amount

Capital

Deficit

Equity
Balance, April 1, 2023

546

$
—

1,549,581

$
155

$
175,316,783

$
(172,604,342)

$
2,712,596
Issuance costs related to issuance of Common Stock, pre-funded warrants and warrants in private placement

—

—

—

—

(78,938)

—

(78,938)
Issuance of Common Stock in connection with the exercise of warrants in the June 2023 Inducement Offering, net of offering costs

—

—

1,724,332

173

2,238,892

—

2,239,065
Exercise of pre-funded warrants into Common Stock

—

—

895,018

89

—

—

89
Deemed dividend of Series B preferred stock

—

—

—

—

(94,324)

—

(94,324)
Issuance of Common Stock from RSU vest

—

—

40,064

4

(4)

—

—
Stock-based compensation

—

—

—

—

292,704

—

292,704
Net loss

—

—

—

—

—

(4,189,232)

(4,189,232)
Balance, June 30, 2023

546

$
—

4,208,995

$
421

$
177,675,113

$
(176,793,574)

$
881,960

Accumulated

Series B Convertible





Additional



Other

Total

Preferred Stock

Common Stock

Paid In

Accumulated

Comprehensive

Stockholders’


Shares

Amount

Shares

Amount

Capital

Deficit

Loss

Deficit
Balance, April 1, 2022

645

$
—

102,613

$
10

$
155,573,631

$
(163,530,886)

$
(1,282,540)

$
(9,239,785)
Issuance of Common Stock at-the-market for cash, net of offering costs

—

—

5,070

1

317,230

—

—

317,231
Deemed dividend of Series B preferred stock

—

—

—

—

(97,125)

—

—

(97,125)
Warrant modification

—

—

—

—

47,300

—

—

47,300
Deemed dividend on warrant modification

—

—

—

—

(47,300)

—

—

(47,300)
Conversion of Series B preferred shares into Common Stock

(14)

—

411

—

—

—

—

—
Stock-based compensation

—

—

—

—

374,907

—

—

374,907
Foreign currency translation adjustment

—

—

—

—

—

—

(136,946)

(136,946)
Net loss

—

—

—

—

—

(5,408,145)

—

(5,408,145)
Balance, June 30, 2022

631

$
—

108,094

$
11

$
156,168,643

$
(168,939,031)

$
(1,419,486)

$
(14,189,863)

~~See accompanying notes to unaudited condensed consolidated financial statements~~

~~-4-~~

~~Table of Contents~~

~~FIRST WAVE BIOPHARMA, INC.~~

~~Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) (unaudited)~~

Series B Convertible



Additional

Total

Preferred Stock

Common Stock

Paid In

Accumulated

Stockholders’


Shares

Amount

Shares

Amount

Capital

Deficit

Equity
Balance, January 1, 2023

550

$
—

995,003

$
100

$
171,275,741

$
(168,533,689)

$
2,742,152
Issuance of Common Stock, pre-funded warrants and warrants in private placement, net of issuance costs

—

—

128,000

13

3,690,960

—

3,690,973
Issuance of Common Stock in connection with the exercise of warrants in the June 2023 Inducement Offering, net of offering costs

—

—

1,724,332

173

2,238,892

—

2,239,065
Exercise of pre-funded warrants into Common Stock

—

—

1,324,493

131

259

—

390
Deemed dividend of Series B preferred stock

—

—

—

—

(181,755)

—

(181,755)
Conversion of Series B preferred shares into Common Stock

(4)

—

70

—

—

—

—
Issuance of Common Stock from RSU vest

—

—

40,064

4

(4)

—

—
Effect of cancelled shares from the 1-for-7 reverse stock split

—

—

(2,967)

—

—

—

—
Stock-based compensation

—

—

—

—

651,020

—

651,020
Net loss

—

—

—

—

—

(8,259,885)

(8,259,885)
Balance, June 30, 2023

546

$
—

4,208,995

$
421

$
177,675,113

$
(176,793,574)

$
881,960


											Accumulated
	Series B Convertible						Additional				Other		Total
	Preferred Stock			Common Stock			Paid In		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Shares	Amount		Capital		Deficit		Loss		Equity
Balance, July 1, 2023	546	$	—	4,208,995	$	421	$	177,675,113	$	(176,793,574)	$	—	$	881,960
Issuance of common stock, pre-funded warrants and warrants in July 2023 offering, net of issuance costs	—		—	610,000		61		1,833,866		—		—		1,833,927
Issuance of common stock in connection with the exercise of warrants in the September 2023 Inducement Offering, net of offering costs	—		—	5,882,036		588		3,706,183		—		—		3,706,771
Exercise of pre-funded warrants into common stock	—		—	2,675,000		267		—		—		—		267
Deemed dividend of Series B preferred stock	—		—	—		—		(49,292)		—		—		(49,292)
Conversion of Series B preferred shares into common stock	(24)		—	417		—		—		—		—		—
Common stock issued to consultants	—		—	50,000		5		75,995		—		—		76,000
Issuance of common stock from RSU vest	—		—	37,031		4		(4)		—		—		—
Stock-based compensation	—		—	—		—		263,330		—		—		263,330
Net loss	—		—	—		—		—		(3,434,158)		—		(3,434,158)
Balance, September 30, 2023	522		—	13,463,479		1,346		183,505,191		(180,227,732)		—		3,278,805

Accumulated

Series B Convertible

Additional

Other

Total

Preferred Stock

Common Stock

Paid In

Accumulated

Comprehensive

Stockholders’


Shares

Amount

Shares

Amount

Capital

Deficit

Loss

Deficit
Balance, January 1, 2022

662

$
—

70,742

$
7

$
147,306,625

$
(153,904,047)

$
(1,224,135)

$
(7,821,550)
Issuance of Common Stock, pre-funded warrants and warrants in registered direct offering, net of issuance costs

—

—

7,857

1

7,972,090

—

—

7,972,091
Issuance of Common Stock at-the-market for cash, net of offering costs

—

—

5,070

1

317,230

—

—

317,231
Exercise of pre-funded warrants into Common Stock

—

—

23,086

2

48,480

—

—

48,482
Deemed dividend of Series B preferred stock

—

—

—

—

(187,917)

—

—

(187,917)
Warrant modification

—

—

—

—

47,300

—

—

47,300
Deemed dividend on warrant modification

—

—

—

—

(47,300)

—

—

(47,300)
Conversion of Series B preferred shares into Common Stock

(31)

—

910

—

—

—

—

—
Common Stock issued to consultants

—

—

429

—

118,999

—

—

118,999
Stock-based compensation

—

—

—

—

593,136

—

—

593,136
Foreign currency translation adjustment

—

—

—

—

—

—

(195,351)

(195,351)
Net loss

—

—

—

—

—

(15,034,984)

—

(15,034,984)
Balance, June 30, 2022

631

$
—

108,094

$
11

$
156,168,643

$
(168,939,031)

$
(1,419,486)

$
(14,189,863)


																	Accumulated
	Series E Convertible			Series D Convertible			Series B Convertible						Additional				Other		Total
	Preferred Stock			Preferred Stock			Preferred Stock			Common Stock			Paid In		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount		Capital		Deficit		Loss		Deficit
Balance, July 1, 2022	—		—	—		—	631	$	—	108,094	$	10	$	156,168,644	$	(168,939,031)	$	(1,419,486)	$	(14,189,863)
Issuance of Series D preferred stock and warrants for cash, net of offering costs	—		—	150		—	—		—	—		—		178,336		—		—		178,336
Issuance of Series E preferred stock, net of offering costs	150		—	—		—	—		—	—		—		20,664		—		—		20,664
Issuance of common stock from the conversion of Series D preferred stock	—		—	(150)		—	—		—	4,761		1		(1)		—		—		—
Issuance of common stock from the conversion of Series E preferred stock	(150)		—	—		—	—		—	4,761		1		(1)		—		—		—
Issuance of common stock at-the-market for cash, net of offering costs	—		—	—		—	—		—	211,968		21		7,373,334		—		—		7,373,355
Deemed dividend of Series B preferred stock	—		—	—		—	—		—	—		—		(110,278)		—		—		(110,278)
Effect of cancelled shares from the 1-for-30 reverse stock split	—		—	—		—	—		—	(12)		—		—		—		—		—
Stock-based compensation	—		—	—		—	—		—	—		—		91,641		—		—		91,641
Foreign currency translation adjustment	—		—	—		—	—		—	—		—		—		—		(35,235)		(35,235)
Net income	—		—	—		—	—		—	—		—		—		4,391,331		—		4,391,331
Balance, September 30, 2022	—	$	—	—	$	—	631	$	—	329,572	$	33	$	163,722,339	$	(164,547,700)	$	(1,454,721)	$	(2,280,049)

See accompanying notes to unaudited condensed consolidated financial statements

-6-

Table of Contents

FIRST WAVE BIOPHARMA, INC.

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) (unaudited)


											Accumulated
	Series B Convertible						Additional				Other		Total
	Preferred Stock			Common Stock			Paid In		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Shares	Amount		Capital		Deficit		Loss		Equity
Balance, January 1, 2023	550	$	—	995,003	$	100	$	171,275,741	$	(168,533,689)	$	—	$	2,742,152
Issuance of common stock, pre-funded warrants and warrants in March 2023 offering, net of issuance costs	—		—	128,000		13		3,690,960		—		—		3,690,973
Issuance of common stock in connection with the exercise of warrants in the June 2023 Inducement Offering, net of offering costs	—		—	1,724,332		173		2,238,892		—		—		2,239,065
Issuance of common stock, pre-funded warrants and warrants in July 2023 offering, net of issuance costs	—		—	610,000		61		1,833,866		—		—		1,833,927
Issuance of common stock in connection with the exercise of warrants in the September 2023 Inducement Offering, net of offering costs	—		—	5,882,036		588		3,706,183		—		—		3,706,771
Exercise of pre-funded warrants into common stock	—		—	3,999,493		398		259		—		—		657
Deemed dividend of Series B preferred stock	—		—	—		—		(231,047)		—		—		(231,047)
Conversion of Series B preferred shares into common stock	(28)		—	487		—		—		—		—		—
Common stock issued to consultants	—		—	50,000		5		75,995		—		—		76,000
Issuance of common stock from RSU vest	—		—	77,095		8		(8)		—		—		—
Effect of cancelled shares from the 1-for-7 reverse stock split	—		—	(2,967)		—		—		—		—		—
Stock-based compensation	—		—	—		—		914,350		—		—		914,350
Net loss	—		—	—		—		—		(11,694,043)		—		(11,694,043)
Balance, September 30, 2023	522		—	13,463,479		1,346		183,505,191		(180,227,732)		—		3,278,805


																	Accumulated
	Series E Convertible			Series D Convertible			Series B Convertible						Additional				Other		Total
	Preferred Stock			Preferred Stock			Preferred Stock			Common Stock			Paid In		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Shares	Amount		Shares	Amount		Shares	Amount		Capital		Deficit		Loss		Deficit
Balance, January 1, 2022	—		—	—		—	662	$	—	70,742	$	7	$	147,306,625	$	(153,904,047)	$	(1,224,135)	$	(7,821,550)
Issuance of Series D preferred stock and warrants for cash, net of offering costs	—		—	150		—	—		—	—		—		178,336		—		—		178,336
Issuance of Series E preferred stock, net of offering costs	150		—	—		—	—		—	—		—		20,664		—		—		20,664
Issuance of common stock from the conversion of Series D preferred stock	—		—	(150)		—	—		—	4,761		1		(1)		—		—		—
Issuance of common stock from the conversion of Series E preferred stock	(150)		—	—		—	—		—	4,761		1		(1)		—		—		—
Issuance of common stock, pre-funded warrants and warrants in registered direct offering, net of offering costs	—		—	—		—	—		—	7,857		1		7,971,931		—		—		7,971,932
Issuance of common stock at-the-market for cash, net of offering costs	—		—	—		—	—		—	217,038		21		7,691,201		—		—		7,691,222
Exercise of pre-funded warrants into common stock	—		—	—		—	—		—	23,086		2		48,011		—		—		48,013
Deemed dividend of Series B preferred stock	—		—	—		—	—		—	—		—		(298,195)		—		—		(298,195)
Warrant modification	—		—	—		—	—		—	—		—		47,300		—		—		47,300
Deemed dividend on warrant modification	—		—	—		—	—		—	—		—		(47,300)		—		—		(47,300)
Conversion of Series B preferred shares into common stock	—		—	—		—	(31)		—	910		—		—		—		—		—
Common stock issued to consultants	—		—	—		—	—		—	429		—		118,990		—		—		118,990
Effect of cancelled shares from the 1-for-30 reverse stock split	—		—	—		—	—		—	(12)		—		—		—		—		—
Stock-based compensation	—		—	—		—	—		—	—		—		684,778		—		—		684,778
Foreign currency translation adjustment	—		—	—		—	—		—	—		—		—		—		(230,586)		(230,586)
Net loss	—		—	—		—	—		—	—		—		—		(10,643,653)		—		(10,643,653)
Balance, September 30, 2022	—	$	—	—	$	—	631	$	—	329,572	$	33	$	163,722,339	$	(164,547,700)	$	(1,454,721)	$	(2,280,049)

See accompanying notes to unaudited condensed consolidated financial statements

~~-5-~~-7-

Table of Contents

FIRST WAVE BIOPHARMA, INC.

Condensed Consolidated Statements of Cash Flows (unaudited)

Six Months Ended June 30,

2023

2022
Cash flows from operating activities:

Net loss

$
(8,259,885)

$
(15,034,984)
Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation

14,637

14,635
Change in right-of-use assets

31,334

46,693
Stock-based compensation

651,020

593,136
Common Stock granted to consultants

—

118,999
Changes in assets and liabilities:

Other receivables

93,014

(70,429)
Prepaid expenses

839,094

612,607
Lease liabilities

(31,985)

(78,228)
Deposits

6,899

9,686
Accounts payable

871,155

1,258,632
Accrued expenses

159,686

32,982
Other liabilities

17,769

(1,410)
Net cash used in operating activities

(5,607,262)

(12,497,681)

Cash flows from financing activities:

Proceeds from issuance of Common Stock, pre-funded warrants and warrants, net of offering costs

3,690,973

8,289,322
Proceeds from exercise of warrants, net of issuance costs

2,239,455

48,482
Payment made related to acquisition

—

(2,414,955)
Repayments of note payable

(450,016)

(479,327)
Net cash provided by financing activities

5,480,412

5,443,522

Net decrease in cash

(126,850)

(7,054,159)

Effect of exchange rate changes on cash

—

(39,516)

Cash and restricted cash, beginning balance

1,384,423

8,248,684
Cash and restricted cash, ending balance

$
1,257,573

$
1,155,009

Supplemental disclosures of cash flow information:

Cash paid for interest

$
14,165

$
8,823

Non-cash investing and financing activities:

Deemed dividend on warrant modifications

$
—

$
(47,300)
Accrued dividends on preferred stock

$
(181,755)

$
(187,917)


	Nine Months Ended September 30,
	2023		2022
Cash flows from operating activities:
Net loss	$	(11,694,043)	$	(10,643,653)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		21,955		21,953
Change in right-of-use assets		47,429		61,681
Stock-based compensation		914,350		684,778
Common stock granted to consultants		76,000		118,990
Changes in assets and liabilities:
Other receivables		93,014		(191,984)
Prepaid expenses		1,272,558		614,809
Lease liabilities		(48,919)		(93,438)
Deposits		6,899		9,714
Accounts payable		(140,749)		875,257
Accrued expenses		514,364		(120,985)
Payable related to acquisition		—		(8,085,045)
Other liabilities		(1,332)		(3,867)
Net cash used in operating activities		(8,938,474)		(16,751,790)

Cash flows from financing activities:
Proceeds from issuance of preferred stock, net		—		199,000
Proceeds from issuance of common stock, pre-funded warrants and warrants, net		5,525,010		7,971,932
Proceeds from exercise of warrants, net of issuance costs		5,946,383		48,013
Issuance of common stock at-the-market for cash, net of offering costs		—		7,691,222
Deferred offering costs		—		(138,684)
Payment made related to acquisition		—		(4,914,955)
Repayments of note payable		(603,494)		(641,236)
Net cash provided by financing activities		10,867,899		10,215,292

Net increase (decrease) in cash and restricted cash		1,929,425		(6,536,498)

Effect of exchange rate changes on cash		—		(33,668)

Cash, cash equivalents and restricted cash, beginning balance		1,384,423		8,248,684
Cash, cash equivalents and restricted cash, ending balance	$	3,313,848	$	1,678,518

Supplemental disclosures of cash flow information:
Cash paid for interest	$	15,414	$	8,824

Non-cash investing and financing activities:
Deemed dividend on warrant modifications	$	—	$	(47,300)
Accrued dividends on preferred stock	$	(231,047)	$	(298,195)

See accompanying notes to unaudited condensed consolidated financial statements

~~-6-~~-8-

Table of Contents

FIRST WAVE BIOPHARMA, INC.

Notes to Unaudited Condensed Consolidated Financial Statements

~~June~~September 30, 2023

Note 1 - The Company and Basis of Presentation

The Company

First Wave BioPharma, Inc. (“First Wave”) and its wholly-owned subsidiary, First Wave Bio, Inc. (“FWB”), are collectively referred to as the “Company”. Effective October 26, 2022, the Company’s wholly-owned subsidiary, AzurRx SAS, was dissolved. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (“GI”) diseases. Non-systemic therapies are non-absorbable drugs that act locally, i.e., in the intestinal lumen, skin or mucosa, without reaching an individual’s systemic circulation.

The Company is currently focused on developing ~~its~~a therapeutic pipeline ~~of gut-restricted GI~~with multiple Phase 2 clinical ~~drug candidates, including~~stage programs built around three proprietary technologies – the biologic ~~adrulipase (formerly MS1819),~~Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and ~~niclosamide,~~chronic pancreatitis patients with exocrine pancreatic insufficiency; Capeserod, a selective 5-HT4 receptor partial agonist which we will pursue for GI indications; and Niclosamide, an oral small molecule with ~~anti-viral and~~ anti-inflammatory ~~properties. The Company’s adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule~~properties for ~~the treatment of exocrine pancreatic insufficiency (“~~~~EPI~~~~”) in~~ patients with ~~cystic fibrosis (“~~CF”)inflammatory bowel diseases such as ulcerative colitis and ~~chronic pancreatitis (“~~CP~~”). The Company’s niclosamide programs leverage proprietary oral and topical formulations to address multiple GI conditions, including IBD indications and viral diseases.~~Crohn’s disease.

The Company is developing its product candidates for a host of GI diseases where there are significant unmet clinical needs and limited therapeutic options, resulting in painful, life threatening and discomforting consequences for patients. Since its inception, the Company has devoted substantially all its efforts to research and development, business development, and raising capital, and has financed its operations through issuance of Common Stock, convertible preferred stock, convertible debt, and other debt/equity instruments.

Risks and Uncertainties

The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development and regulatory success, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to secure additional capital to fund clinical trials and operations.

In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements and the specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these financial statements.

In addition, the Company is subject to other challenges and risks specific to its business, its ability to maintain compliance with the continued listing requirements of The Nasdaq ~~Capital~~Stock Market LLC and its ability to execute on its strategy, as well as risks and uncertainties common to companies in the biotechnology and pharmaceutical industries with development and commercial operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its drug candidates; delays or problems in the manufacture and supply of its drug candidates; loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or drug candidates; pharmaceutical product development and the inherent uncertainty of clinical success; the challenges of protecting and enhancing our intellectual property rights; and complying with applicable regulatory requirements.

Principles of Consolidation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and include the accounts of First Wave and its wholly owned subsidiaries, FWB and AzurRx SAS, which was dissolved effective October 26, 2022. Intercompany transactions and balances have been eliminated upon consolidation.

~~-7-~~-9-

Table of Contents

In our opinion, the accompanying unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations, and cash flows. The condensed consolidated balance sheet at December 31, 2022, has been derived from audited financial statements of that date. The unaudited interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the SEC. The Company believes that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim condensed consolidated financial statements are read in conjunction with the audited financial statements and notes previously distributed in our Annual Report Form 10-K for the year ended December 31, 2022, filed with the SEC on March 20, 2023.

Going Concern Uncertainty

The accompanying unaudited interim condensed consolidated financial statements have been prepared as if the Company will continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. On ~~June~~September 30, 2023, the Company had cash and cash equivalents of approximately ~~$1.2~~$3.3 million, an accumulated deficit of approximately ~~$176.8~~$180.2 million, and a working capital ~~deficiency~~ of approximately ~~$0.9~~$1.5 million. ~~Subsequent to June 30, 2023 through August 14, 2023, the Company has raised aggregate gross proceeds of approximately $2.1 million from the July 2023 Offering.~~ The Company has incurred recurring losses, has experienced recurring negative operating cash flows, and requires significant cash resources to execute its business plans. The Company anticipates having sufficient cash to fund planned operations through ~~September~~December 2023, however, the acceleration or reduction of cash outflows by Company management can significantly impact the timing for the need to raise additional capital to complete development of its products. Historically, the Company’s major sources of cash have been comprised of proceeds from various public and private offerings of its capital stock. The Company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities in order to continue to execute its development plans and continue operations.

Without adequate working capital, the Company may not be able to meet its obligations and continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern one year from the date these financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Note 2 - Significant Accounting Policies and Recent Accounting Pronouncements

Use of Estimates

The accompanying unaudited condensed consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may differ from those estimates.

Reverse Stock Split

On January 18, 2023, the Company effected a reverse stock split, whereby every seven shares of the Company’s issued and outstanding Common Stock was converted automatically into one issued and outstanding share of Common Stock, but without any change in the number of authorized shares of Common Stock and the par value per share.

On August 26, 2022, the Company effected a reverse stock split, whereby every thirty shares of the Company’s issued and outstanding common stock was converted automatically into one issued and outstanding share of common stock, but without any change in the number of authorized shares of common stock and the par value per share.

All share and per share amounts have been retroactively restated to reflect the reverse stock splits referenced above.

Cash, ~~and~~ Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. All cash and cash equivalent balances were highly liquid at ~~June~~September 30, 2023 and December 31, 2022. As of ~~June~~September 30, 2023 and December 31, 2022, the Company has classified approximately $0.02 million as restricted cash.

~~-8-~~-10-

Table of Contents

Concentrations of Credit Risk

Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may from time to time have cash in banks in excess of FDIC insurance limits. At ~~June~~September 30, 2023 the Company had approximately ~~$1.2~~$3.2 million in one account in the U.S. which was in excess of these limits. The Company has not experienced any losses to date resulting from this practice. The Company mitigates its risk by maintaining the majority of its cash and equivalents with high quality financial institutions.

Fair Value Measurements

The Company follows Accounting Standards Codification (“(“ASC”) Topic 820-10, Fair Value Measurements and Disclosures (“ASC 820”), which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.

As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an instrument’s level within the fair value hierarchy is based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the financial instrument.

The Company recognizes transfers between levels as if the transfers occurred on the last day of the reporting period.

Foreign Currency Translation

For foreign subsidiaries with operations denominated in a foreign currency, assets and liabilities were translated to U.S. dollars, which iswas the functional currency, at period end exchange rates. Income and expense items were translated at average rates of exchange prevailing during the periods presented. Gains and losses from translation adjustments were accumulated in a separate component of stockholders’ equity up until the dissolution of AzurRx SAS in October 2022, at which time cumulative translation adjustments were recognized as a loss for the year ended December 31, 2022.

Goodwill

Goodwill represents the excess of the purchase price of the acquired business over the fair value of amounts assigned to assets acquired and liabilities assumed. Goodwill and other intangible assets with indefinite useful lives are reviewed for impairment annually or more frequently if events or circumstances indicate impairment may be present. Any excess in carrying value over the estimated fair value is charged to results of operations. The Company has not recognized any impairment charges through ~~June~~September 30, 2023 related to goodwill.

Impairment of Long-Lived Assets

The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, Property, Plant and Equipment (“ASC 360”). Potential impairment is assessed when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. Recoverability of these assets is assessed based on undiscounted expected future cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market trends and product development cycles. If impairments are identified, assets are written down to their estimated fair value. The Company has not recognized any impairment charges through ~~June~~September 30, 2023.

~~-9-~~-11-

Table of Contents

Leases

The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ROU”) assets, and lease liability obligations are included in the Company’s balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liability obligations represent its obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company’s leases typically do not provide an implicit rate, the Company estimates its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives and lease direct costs. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. Please refer to Note 1213 for additional information.

License Agreements

The Company records payments related to license agreements for assets acquired that have not reached technological feasibility and which have no alternative future use, as research and development expenses. On September 13, 2023, the Company entered into a license agreement with Sanofi to license Capeserod, a selective 5-HT4 receptor partial agonist, which the Company will repurpose and develop for gastrointestinal (“GI”) indications. Under the terms of the agreement, the Company received from Sanofi an exclusive, global license for Capeserod and assumed responsibility for all future clinical development (see Note 12).

Research and Development

Research and development costs are charged to operations when incurred and are included in operating expense, except for goodwill related to patents. Research and development costs consist principally of compensation of employees and consultants that perform the Company’s research activities, payments to third parties for preclinical and non-clinical activities, expenses with clinical research organizations (“CROs”), investigative sites, consultants and contractors that conduct or provide other services relating to clinical trials, costs to acquire drug product, drug supply and clinical trial materials from contract development and manufacturing organization (“CDMOs”) and third-party contractors relating to chemistry, manufacturing and controls (“CMC”) efforts, the fees paid for and to maintain the Company’s licenses, ~~amortization of intangible assets related to the acquisition of adrulipase,~~ and research and development costs related to ~~adrulipase~~Adrulipase, Capeserod, and ~~niclosamide.~~Niclosamide. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management’s estimates of the work performed under service agreements, milestones achieved and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.

Research and Development – Intellectual Property Acquired

The Company records intellectual property in asset acquisitions that have not reached technological feasibility and which have no alternative future use, as an expense at the acquisition date. On September 13, 2021, the Company entered into an agreement with FWB for the acquisition of intellectual property and patents for the worldwide, exclusive right to develop, manufacture, and commercialize proprietary formulations of ~~niclosamide~~Niclosamide for the fields of treating ICI-AC and COVID-19 in humans, which was accounted for as an asset acquisition (see Note 4).

Stock-Based Compensation

The Company’s board of directors (the “Board”) and stockholders have adopted and approved the Amended and Restated 2014 Omnibus Equity Incentive Plan (the “2014 Plan”) which took effect on May 12, 2014, and the 2020 Omnibus Equity Incentive Plan, which took effect on September 11, 2020 (the “2020 Plan”). From the effective date of the 2020 Plan, no new awards have been or will be made under the 2014 Plan. The Company accounts for its stock-based compensation awards to employees, consultants, and Board members in accordance with ASC Topic 718, Compensation-Stock Compensation (“ASC 718”). ASC 718 requires all stock-based payments to employees, consultants, and Board members, including grants of employee stock options, to be recognized in the statements of operations by measuring the fair value of the award on the date of grant and recognizing this fair value as stock-based compensation using a straight-line method over the requisite service period, generally the vesting period.

-12-

Table of Contents

For awards with performance conditions that affect their vesting, such as the occurrence of certain transactions or the achievement of certain operating or financial milestones, recognition of fair value of the award occurs when vesting becomes probable.

The Company estimates the grant date fair value of stock option awards using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock.

~~-10-~~

~~Table of Contents~~

Recent Accounting Pronouncements

In August 2020, the Financial Accounting Standards Board (the “FASB”) issued accounting pronouncement ASU 2020-06 – Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) related to the measurement and disclosure requirements for convertible instruments and contracts in an entity’s own equity. The pronouncement simplifies and adds disclosure requirements for the accounting and measurement of convertible instruments and the settlement assessment for contracts in an entity’s own equity. As a smaller reporting company, as defined by the U.S. Securities and Exchange Commission (the “SEC”), this pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company early adopted ASU 2020-06 effective January 1, 2022.

In June 2016, the FASB issued accounting pronouncement ASU 2016-13 – Measurement of Credit Losses on Financial Statements (“ASU 2016-13”). The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. In November 2019, the FASB issued ASU 2019-10 – Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates, which amended the effective date for certain companies. The standard is effective for public companies eligible to be smaller reporting companies for annual and interim periods beginning after December 15, 2022. The Company adopted ASU 2016-13 effective for the year ended December 31, 2022 and its adoption did not have a material effect on its financial statements and related disclosures.

In June 2022, the FASB issued ASU 2022-03 - Fair Value Measurement, or Topic 820: Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). This new standard clarifies the guidance in Topic 820 when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security and introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The Company has assessed the impact of the update and determined it does not have a material impact on the accompanying financial statements and disclosures.

The Company has evaluated other recently issued accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.

Note 3 - Fair Value Disclosures

Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value.

~~-11-~~-13-

Table of Contents

The fair value of the Company’s financial instruments are as follows:


			Fair Value Measured at Reporting Date										Fair Value Measured at Reporting Date
			Using										Using
	Carrying										Carrying
	Amount		Level 1		Level 2		Level 3		Fair Value		Amount		Level 1		Level 2		Level 3		Fair Value
June 30, 2023 (unaudited):
September 30, 2023 (unaudited):
Money market funds	$	11,925	$	11,925	$	—	$	—	$	11,925	$	12,086	$	12,086	$	—	$	—	$	12,086
Note payable		153,478		—		153,478		—		153,478		—		—		—		—		—

December 31, 2022:
Money market funds		509,890		509,890		—		—		509,890		509,890		509,890		—		—		509,890
Note payable	$	603,494	$	—	$	603,494	$	—	$	603,494	$	603,494	$	—	$	603,494	$	—	$	603,494

At ~~June~~September 30, 2023 and December 31, 2022, the Company had no other assets or liabilities that are subject to fair value methodology and estimation in accordance with U.S. GAAP.

Note 4 – Asset Acquisition

The Asset Acquisition

During the ~~six~~nine months ended ~~June~~September 30, 2022, the Company paid an aggregate of $2.4 million in cash towards the purchase price of FWB in accordance with the terms of an Agreement and Plan of Merger dated as of September 13, 2021 (the “Merger Agreement”) and a settlement agreement reached on November 21, 2021 (the “November 2021 Settlement Agreement”).

On May 19, 2022, Fortis Advisors LLC, the hired representative (in such capacity, the “Representative”) of the former stockholders of FWB in connection with the Merger Agreement, filed a complaint against the Company in the Court of Chancery in the State of Delaware (the “FWB Action”) for breach of contract and anticipatory repudiation or for unjust enrichment. The FWB Action sought specific performance of the Company’s obligations under the Merger Agreement and the November 2021 Settlement Agreement, including all payments then owed and to be owed to the Representative, and damages at the maximum amount permitted by law. On July 29, 2022, the Company reached an agreement with the Representative to settle the FWB Action and to restructure the Company’s obligations to the former FWB stockholders (the “July 2022 Term Sheet”). The Company agreed to pay the Representative: (i) $1.5 million in cash on July 29, 2022; (2) $1.0 million in cash no later than September 29, 2022 (the “Second Payment”); and (iii) $2.0 million on the earlier of November 30, 2022 and the completion by the Company of one or more qualifying equity offerings (collectively, the “Payments”). The Representative is also entitled to receive future cash payments conditioned on the achievement of certain development milestones for ~~adrulipase~~Adrulipase and to a percentage of any consideration received by the Company in the event of a license or sale of ~~adrulipase,~~Adrulipase, subject to a cap. The Representative is also entitled to receive a percentage of the consideration received by the Company in the event of a license or sale of ~~niclosamide~~Niclosamide and will retain its existing milestone payment rights with respect to ~~niclosamide.~~Niclosamide. In the event that the consideration received by the Company in connection with the sale or license of ~~adrulipase~~Adrulipase or ~~niclosamide~~Niclosamide consists of securities or other non-cash consideration, the Representative will have the right to elect either to receive its payment in such form of consideration or to cause the licensee or acquirer to assume the obligations described herein. In the event of a “Company Sale” (as defined in the July 2022 Term Sheet), the Representative is entitled to receive a pro rata share of the total consideration received by the Company or its stockholders up to $4.0 million (plus any unpaid Payments whether or not then due) based on a formula set forth in the July 2022 Term Sheet. In certain circumstances, the Representative has the right to treat a “Company Sale” as a sale of ardulipase or ~~niclosamide,~~Niclosamide, as applicable, and to treat the Company Sale as a sale of the related asset and to receive the consideration with respect thereto described herein.

In the July 2022 Term Sheet, the Representative agreed to stay the FWB Action for a period of 90 days and to eliminate the Company’s obligation to pay a portion of any offering proceeds to the Representative. In addition, the Company’s obligation to use commercially reasonable efforts to develop ~~niclosamide~~Niclosamide will be deferred for a period of 24 months from the date of the July 2022 Term Sheet. Effective upon the Second Payment, the Representative dismissed the FWB Action with prejudice and extinguished the remaining fixed payment obligations owed to the former FWB shareholders. On November 30, 2022, the Company entered into a formal settlement agreement with the Representative on substantially the same terms as the July 2022 Term Sheet (the “November 2022 Settlement Agreement”).

~~-12-~~-14-

Table of Contents

Accounting Treatment

Under the July 2022 Term Sheet, the $1.5 million in cash due and paid on July 29, 2022, as well as the Second Payment due and paid in September 2022, were recorded as a reduction to current liabilities for the three months ended September 30, 2022. Effective upon the Second Payment, the approximately $10.1 million of remaining fixed payment obligations previously owed to the former FWB shareholders was settled. The third payment obligation of $2.0 million due and paid by November 30, 2022 was recorded as research and development expense in the three months ended December 31, 2022.

The remaining unachieved potential milestone payments and revenue share are not yet considered probable, therefore have not been accrued as of ~~June~~September 30, 2023. Depending on the status of development at the time a contingent payment is recognized, the Company may determine that the payment should be expensed as research and development or be capitalized as an intangible asset. This determination will be based on the facts and circumstances that exist at the time a contingent payment is recognized.

Note 5 – Property, Equipment and Leasehold Improvements

Property, equipment, and leasehold improvements consisted of the following:


	June 30,				September 30,
	2023		December 31,		2023		December 31,
	(unaudited)		2022		(unaudited)		2022
Computer equipment and software	$	11,540	$	11,540	$	11,540	$	11,540
Office equipment		48,278		48,278		48,278		48,278
Leasehold improvements		28,000		28,000		28,000		28,000
Total property, plant, and equipment		87,818		87,818		87,818		87,818
Less accumulated depreciation		(58,616)		(43,979)		(65,934)		(43,979)
Property, plant and equipment, net	$	29,202	$	43,839	$	21,884	$	43,839

Depreciation expense for each of the three months ended ~~June~~September 30, 2023 and 2022 was approximately $7,300, and ~~$7,300, respectively, and~~ for each of the ~~six~~nine months ended ~~June~~September 30, 2023 and 2022 was approximately ~~$14,600 and $14,600, respectively.~~$22,000.

Note 6 –Goodwill

Goodwill is as follows:


	Goodwill		Goodwill
Balance on January 1, 2022	$	1,911,705	$	1,911,705
Foreign currency translation		(227,523)		(227,523)
Balance on December 31, 2022		1,684,182		1,684,182
Foreign currency translation		—		—
Balance on June 30, 2023 (unaudited)	$	1,684,182
Balance on September 30, 2023 (unaudited)			$	1,684,182

Note 7 - Accrued Expenses

Accrued expenses consisted of the following:


	June 30,				September 30,
	2023		December 31,		2023		December 31,
	(unaudited)		2022		(unaudited)		2022
Clinical trials	$	301,226	$	5,340
License agreement					$	500,000	$	—
Professional fees		178,636		309,867		244,215		309,867
Consulting fees		—		4,969		82,974		4,969
Payroll and benefits						7,351		—
Clinical trials						—		5,340
Total accrued expenses	$	479,862	$	320,176	$	834,540	$	320,176

~~-13-~~-15-

Table of Contents

Note 8 – Note Payable

Directors and Officer’s Liability Insurance

On November 30, 2022, the Company entered into 9-month financing agreements for its directors and officer’s liability insurance, as well as other corporate insurances, in the amount of approximately $677,000 that bears interest at an annual rate of 6.79%. Monthly payments, including principal and interest, of approximately $77,000 per month. The balance due under these financing agreements was approximately ~~$153,000~~$0 and $603,000 at ~~June~~September 30, 2023 and December 31, 2022, respectively.

Note 9 – Capital Stock

Common Stock and Preferred Stock

The Company’s amended and restated certificate of incorporation, as amended to date, (the “Charter”) authorizes the issuance of up to 50,000,000 shares of Common Stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share.

On August 26, 2022, the Company effected a reverse stock split, whereby every thirty shares of the Company’s issued and outstanding Common Stock was converted automatically into one issued and outstanding share of Common Stock, but without any change in the number of authorized shares of Common Stock and the par value per share.

All share and per share amounts have been retroactively restated to reflect the reverse stock splits referenced above.

The Company had ~~4,208,995~~13,463,479 and 995,003 shares of its Common Stock issued and outstanding on ~~June~~September 30, 2023 and December 31, 2022, respectively.

The Company had approximately ~~545.94~~521.72 and 550.17 shares of Series B preferred stock issued and outstanding on ~~June~~September 30, 2023 and December 31, 2022, respectively.

The Company had 0 shares of Series C, Series D, Series E and Series F preferred stock issued and outstanding on ~~June~~September 30, 2023 and December 31, 2022.

Most Favored Nations Exchange Right and Waiver Agreements

In the event the Company effects any issuance by the Company or any of its subsidiaries of Common Stock or Common Stock equivalents for cash consideration, or a combination of units thereof (a “Subsequent Financing”), each holder of the Series B Preferred Stock had the right, subject to certain exceptions set forth in the Series B Certificate of Designations, at its option, to exchange (in lieu of cash subscription payments) all or some of the Series B Preferred Stock then held (with a value per share of Series B Preferred Stock equal to the stated value of each share of Series B Preferred Stock, or ~~$7,700.00,~~$7,700, plus accrued and unpaid dividends thereon, of the Series B Preferred Stock (the “Exchange Amount”)) for any securities or units issued in a Subsequent Financing on dollar-for-dollar basis (the “Series B Exchange Right”).

Between February 1, 2022 and February 7, 2022, the Company entered into waiver agreements (the “Waiver”) with certain holders of Series B Preferred Stock, pursuant to which the Company agreed to pay a cash waiver fee equal to ten percent of the stated value of the shares of Series B Preferred Stock held by such holder (other than holders who are insiders who did not receive a cash waiver fee) and such holder agreed to irrevocably waive its Series B Exchange Right with respect to any Subsequent Financing that occurred from and after the date of the Waiver until December 31, 2022.

~~-14-~~-16-

Table of Contents

During the ~~six~~nine months ended ~~June~~September 30, 2022, the Company entered into Waivers with holders of approximately $2.88 million of stated value of Series B Preferred Stock. The Company also entered into Waivers with Company insiders holding approximately $0.047 million of stated value of Series B Preferred Stock for which the Company did not pay a waiver fee. The cash waivers paid of approximately $0.233 million were recorded as other expense on the Company’s condensed consolidated statements of operations for the ~~six~~nine months ended ~~June~~September 30, 2022.

Effective May 12, 2022, the holders of 81.3% of the outstanding shares of the Series B Preferred Stock (the “Consenting Holders”) permanently waived for themselves and all other holders of the Series B Preferred Stock the Series B Exchange Right with respect to any Subsequent Financing occurring on or after January 1, 2022 (the “Permanent Waiver”). Holders of Series B Preferred Stock as of the April 27, 2022 record date were entitled to notice of and to consent to the Permanent Waiver (the “Record Holders”).

Pursuant to the terms of a Waiver Agreement entered into by the Company and the Consenting Holders (the “Waiver Agreement”), the Company permanently reduced the exercise price of the Series B Warrants originally issued on July 16, 2020 (the “Series B Warrants”) held by the Consenting Holders to $52.50 per share or, in the case of Consenting Holders who are officers and directors of the Company, $69.174 (the “Exercise Price Reduction”). Only Consenting Holders are entitled to the Exercise Price Reduction. Series B Warrants to purchase an aggregate of approximately 1,196 shares of Common Stock received the Exercise Price Reduction which was effective as of the Expiration Date. As a result of the Exercise Price Reduction of the Series B Warrants described above, the Company recorded a deemed dividend of approximately $0.047 million for the ~~year~~nine months ended ~~December 31,~~September 30, 2022.

From inception through ~~June~~September 30, 2023, (i) holders of approximately 1,839.76 shares of Series B Preferred Stock with an aggregate Exchange Amount of approximately $14.4 million had previously elected to exercise their Series B Exchange Rights into Series C Preferred Stock, convertible into an aggregate of 9,058 shares of Common Stock (which conversion the Company has elected to make in full), and additional warrants exercisable for up to an aggregate of 9,058 shares of Common Stock, (ii) holders of approximately ~~99.200~~123.42 shares of Series B Preferred Stock with an aggregate Exchange Amount of approximately ~~$880,000~~$1.1 million had previously elected to exercise their Series B Exchange Rights into ~~1,552~~1,969 shares of Common Stock with no warrants, and (iii) holders of approximately 30.91 shares of Series B Preferred Stock with an aggregate Exchange Amount of approximately $265,000 had previously elected to exercise their Series B Exchange Rights into 909 shares of Common Stock, and additional Series C Warrants exercisable for up to an aggregate of 909 shares of Common Stock.

At The Market Agreement with H.C. Wainwright

On May 26, 2021, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent, pursuant to which the Company may issue and sell, from time to time, through Wainwright, shares of its Common Stock, and pursuant to which Wainwright may sell its Common Stock by any method permitted by law deemed to be an “at the market offering” as defined by Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. The Company will pay Wainwright a commission of 3.0% of the aggregate gross proceeds from each sale of Common Stock. As of May 24, 2022, the Company was authorized to offer and sell up to $8.0 million of its Common Stock pursuant to the ATM Agreement over 12-month periods. During the year ended December 31, 2022, the Company issued and sold an aggregate of 217,036 shares of Common Stock under the ATM Agreement for which the Company received gross proceeds of approximately $8.0 million less issuance costs incurred of approximately $309,000. As of ~~June~~September 30, 2023, the maximum dollars authorized under the ATM Agreement were issued.

September 2023 Inducement Offering

On September 14, 2023, the Company entered into warrant exercise inducement offer letters with certain holders (the “September 2023 Holders”) of warrants to purchase shares of the Company’s Common Stock (the “September 2023 Existing Warrants”) pursuant to which the September 2023 Holders agreed to exercise for cash their September 2023 Existing Warrants to purchase 5,882,036 shares of the Company’s Common Stock, in the aggregate, at a reduced exercised price of $0.43 per share, in exchange for the Company’s agreement to issue new warrants (the “September 2023 Inducement Warrants”) on substantially the same terms as the September 2023 Existing Warrants as described below, to purchase up to 11,764,072 shares of the Company’s Common Stock (the “September 2023 Inducement Warrant Shares”) and a cash payment of $0.125 per September 2023 Inducement Warrant Share which was paid in full upon the exercise of the September 2023 Existing Warrants (the “September 2023 Inducement Offering”). The Company received aggregate gross proceeds of approximately $4.0 million from the exercise of the September 2023 Existing Warrants by the Holders and the sale of the September 2023 Inducement Warrants. The Company engaged Roth Capital Partners, LLC (“Roth”) to act as its financial advisor in connection with the transactions summarized above and paid Roth $220,000 for its services.

-17-

Table of Contents

July 2023 Offering

On July 21, 2023, the Company completed an offering (the “July 2023 Offering”) for an aggregate of (i) 610,000 shares of Common Stock, (ii) pre-funded warrants (the “July 2023 Pre-Funded Warrants”) to purchase up to an aggregate of 2,675,000 shares of Common Stock, and (iii) common warrants (the “July 2023 Warrants”) to purchase up to an aggregate of 6,570,000 shares of Common Stock. The public offering price for each share of Common Stock and accompanying July 2023 Warrant to purchase one share of Common Stock was $0.64 per share. The July 2023 Pre-Funded Warrants have an exercise price of $0.0001 per share, are exercisable immediately and will expire when exercised in full. To date, pre-funded warrants have been exercised to purchase 2,675,000 shares of Common Stock. The July 2023 Warrants have an exercise price of $0.64 per share, are exercisable immediately and will expire five years from the initial exercise date.

The Company received gross proceeds of approximately $2.1 million less placement agent’s fees and other offering expenses of approximately $250,000.

June 2023 Inducement Offering

On June 13, 2023, the Company entered into warrant exercise inducement offer letters with certain holders (the “June 2023 Holders”) of warrants to purchase shares of the Company’s Common Stock (the “June 2023 Existing Warrants”) pursuant to which the June 2023 Holders agreed to exercise for cash their June 2023 Existing Warrants to purchase 1,724,332 shares of the Company’s Common Stock, in the aggregate, at a reduced exercised price of $1.15 per share, in exchange for the Company’s agreement to issue new warrants (the “June 2023 Inducement Warrants”) on substantially the same terms as the June 2023 Existing Warrants as described below, to purchase up to 3,448,664 shares of the Company’s Common Stock (the “June 2023 Inducement Warrant Shares”) and a cash payment of $0.125 per June 2023 Inducement Warrant Share which was paid in full upon the exercise of the June 2023 Existing Warrants (the “June 2023 Inducement Offering”). The Company received aggregate gross proceeds of approximately $2.4 million from the exercise of the June 2023 Existing Warrants by the June 2023 Holders and the sale of the June 2023 Inducement Warrants. The Company engaged Roth ~~Capital Partners, LLC (“~~~~Roth~~”) to act as its financial advisor in connection with the transactions summarized above and paid Roth $150,000 for its services.

~~-15-~~

~~Table of Contents~~

March 2023 Private Placement

On March 15, 2023, the Company completed a private placement offering (the “March 2023 Offering”) priced at market under Nasdaq rules, for an aggregate of (i) 128,000 shares of Common Stock, (ii) pre-funded warrants (the “March 2023 Pre-Funded Warrants”) to purchase up to an aggregate of 895,018 shares of Common Stock and (iii) common warrants (the “March 2023 Warrants”) to purchase up to an aggregate of 2,046,036 shares of Common Stock. The public offering price for each share of Common Stock and accompanying March 2023 Warrant to purchase one share of Common Stock was $3.91 per share. The March 2023 Pre-Funded Warrants have an exercise price of $0.0001 per share, are exercisable immediately and will expire when exercised in full. The March 2023 Warrants have an exercise price of $3.66 per share, are exercisable immediately and will expire five years from the initial exercise date.

The Company received gross proceeds of approximately $4.0 million less placement agent’s fees and other offering expenses of approximately $300,000.

July 2022 Private Placement

On July 15, 2022, the Company completed a private placement (the “July 2022 Offering”) in which the Company issued an aggregate of (i) 150 shares of the Company’s Series D Preferred Stock, with a stated value $1,000 per share, convertible into an aggregate of 4,761 shares of the Common Stock, (ii) 150 shares of the Company’s Series E Preferred Stock, with a stated value $1,000 per share, convertible into an aggregate of 4,761 shares of Common Stock, and (iii) Series D Warrants to purchase up to an aggregate of 9,522 shares of Common Stock (the “July 2022 Warrants”). The Series D Preferred Stock are convertible into an aggregate of 4,761 shares of Common Stock at a conversion price of $31.50 per share and the Series E Preferred Shares are convertible, following the August 26, 2022 reverse stock split, into an aggregate of 4,761 shares of Common Stock at a conversion price of $31.50 per share. The July 2022 Warrants have an exercise price of $31.50 per share and will expire five years from the initial exercise date. The Company received gross proceeds of approximately $300,000 from the July 2022 Offering, before deducting the offering expenses payable by the Company.

-18-

Table of Contents

As compensation to Wainwright, who was the exclusive placement agent in connection with the July 2022 Offering, the Company paid Wainwright a cash fee of 7% of the aggregate gross proceeds raised and reimbursement of certain expenses and legal fees. The Company also issued to designees of Wainwright in a private placement warrants (the “Placement Agent Warrants”) to purchase up to 571 shares of Common Stock. The Placement Agent Warrants were cancelled and terminated on October 5, 2022. None of the Placement Agent Warrants were exercised prior to cancellation and termination.

During the three months ended September 30, 2022, all of the Series D Preferred Shares and the Series E Preferred Shares were converted into 9,522 shares of Common Stock.

March 2022 Registered Direct Offering

On March 2, 2022, the Company completed a registered direct offering (the “March 2022 Offering”) priced at the market under Nasdaq rules for an aggregate of 7,857 shares of Common Stock, pre-funded warrants exercisable for an aggregate of up to 23,086 shares of Common Stock (the “March 2022 Pre-Funded Warrants”), and warrants (the “March 2022 Warrants”) exercisable for an aggregate of up to 30,943 shares of Common Stock. The public offering price for each share of Common Stock and accompanying March 2022 Warrant to purchase one share of Common Stock was $290.85, and the public offering price for each March 2022 Pre-Funded Warrant and accompanying March 2022 Warrant to purchase one share of Common Stock was $288.75. The total net proceeds from the March 2022 Offering were approximately $8.0 million. The March 2022 Warrants have an exercise price of $264.60 per share and will be exercisable for five years from the issuance date. The March 2022 Pre-Funded Warrants are exercisable for one share of Common Stock at an exercise price of $2.10 per share and will expire when exercised in full. Additionally, the Company issued warrants to the placement agent (the “March 2022 Placement Agent Warrants”) to purchase 1,856 shares of Common Stock, which was equal to 6.0% of the aggregate number of shares of Common Stock and March 2022 Pre-Funded Warrants placed in the March 2022 Offering. The March 2022 Placement Agent Warrants have a term of five years from the date of the prospectus supplement relating to the March 2022 Offering and an exercise price of $363.30 per share.

The Company received gross proceeds of approximately $9.0 million less placement agent’s fees and other offering expenses of approximately $1.0 million.

Common Stock Issuances

Issuances for the Three Months Ended ~~June~~September 30, 2023

During the three months ended ~~June~~September 30, 2023, the Company issued 610,000 shares of Common Stock under the July 2023 Offering for which the Company received net proceeds of approximately $1.8 million.

During the three months ended September 30, 2023, the Company issued 5,882,036 shares of Common Stock upon the exercise of an aggregate of 5,882,036 investor warrants for which the Company received net proceeds of approximately $3.7 million (See Note 10).

During the three months ended September 30, 2023, the Company issued an aggregate of 2,675,000 shares of Common Stock upon the conversion of pre-funded warrants issued at a par value of $0.0001.

During the three months ended September 30, 2023, the Company issued an aggregate of 417 shares of Common Stock upon the exchange of an aggregate of 24.22 shares of Series B Preferred Stock with a stated value of approximately $186,500 plus accrued dividends of approximately $43,300.

During the three months ended September 30, 2023, the Company issued an aggregate of 50,000 shares of its Common Stock to consultants with a grant date fair value of approximately $76,000 for investor relations services provided, which was recorded as stock-based compensation and included as part of general and administrative expense.

During the three months ended September 30, 2023, the Company issued an aggregate of 37,031 shares of Common Stock upon the vesting of restricted stock units (“RSUs”) (See Note 11).

-19-

Table of Contents

Issuances for the Nine Months Ended September 30, 2023

During the nine months ended September 30, 2023, the Company issued 128,000 shares of Common Stock under the March 2023 Offering for which the Company received net proceeds of approximately $3.7 million.

During the nine months ended September 30, 2023, the Company issued 1,724,332 shares of Common Stock upon the exercise of an aggregate of 1,724,332 investor warrants for which the Company received net proceeds of approximately $2.2 million (See Note 10).

During the ~~three~~nine months ended ~~June~~September 30, 2023, the Company issued ~~an aggregate of 895,018 shares of Common Stock upon the conversion of pre-funded warrants issued at a par value of $0.0001.~~

~~During the three months ended June 30, 2023, the Company issued an aggregate of 40,064 shares of Common Stock upon the vesting of restricted stock units (“~~~~RSUs~~~~”) (See Note 11).~~

~~Issuances for the Six Months Ended June 30, 2023~~

~~During the six months ended June 30, 2023, the Company issued 128,000~~610,000 shares of Common Stock under the ~~March~~July 2023 Offering for which the Company received net proceeds of approximately ~~$3.7~~$1.8 million.

During the ~~six~~nine months ended ~~June~~September 30, 2023, the Company issued ~~1,724,332~~5,882,036 shares of Common Stock upon the exercise of an aggregate of ~~1,724,332~~5,882,036 investor warrants for which the Company received net proceeds of approximately ~~$2.2~~$3.7 million (See Note 10).

During the ~~six~~nine months ended ~~June~~September 30, 2023, the Company issued an aggregate of ~~1,324,493~~3,999,493 shares of Common Stock upon the conversion of pre-funded warrants issued at a par value of $0.0001 (See Note 10).

~~-16-~~

~~Table of Contents~~

During the ~~six~~nine months ended ~~June~~September 30, 2023, the Company issued an aggregate of 70487 shares of Common Stock upon the exchange of an aggregate of ~~4.23~~28.45 shares of Series B Preferred Stock with a stated value of approximately ~~$32,600~~$219,000 plus accrued dividends of approximately ~~$6,200.~~$49,500.

During the ~~six~~nine months ended ~~June~~September 30, 2023, the Company issued an aggregate of ~~40,064~~50,000 shares of its Common Stock to consultants with a grant date fair value of approximately $76,000 for investor relations services provided, which was recorded as stock-based compensation and included as part of general and administrative expense.

During the nine months ended September 30, 2023, the Company issued an aggregate of 77,095 shares of Common Stock upon the vesting of RSUs (See Note 11).

During the ~~six~~nine months ended ~~June~~September 30, 2023, the Company cancelled an aggregate of 2,967 shares of Common Stock in connection with the 1-for-7 reverse stock split on January 18, 2023.

Issuances for the Three Months Ended ~~June~~September 30, 2022

During the three months ended ~~June~~September 30, 2022, the Company issued an aggregate of 9,522 shares of Common Stock upon the conversion of Series E and Series D preferred stock.

During the three months ended September 30, 2022, the Company issued and sold an aggregate of ~~5,070~~211,968 shares of Common Stock under the ATM Agreement for which the Company received net proceeds of approximately ~~$317,000.~~$7.4 million.

During the three months ended ~~June~~September 30, 2022, the Company cancelled an aggregate of 12 shares of Common Stock in connection with the 30-for-1 reverse stock split on August 26, 2022.

Issuances for the Nine Months Ended September 30, 2022

During the nine months ended September 30, 2022, the Company issued an aggregate of ~~411~~9,522 shares of Common Stock ~~and accompanying warrants (the “~~~~Exchange Warrants~~”) upon the ~~exchange of an aggregate of 13.87 shares~~conversion of Series ~~B Preferred Stock with a stated value of approximately $107,000 plus accrued dividends of approximately $13,000. The Exchange Warrants have an exercise price of $264.60 per share~~E and ~~will be exercisable for five years from the issuance date.~~

~~Issuances for the Six Months Ended June 30, 2022~~Series D preferred stock.

During the ~~six~~nine months ended ~~June~~September 30, 2022, the Company issued 7,857 shares of Common Stock under the March 2022 Offering for which the Company received net proceeds of approximately $8.0 million.

During the ~~six~~nine months ended ~~June~~September 30, 2022, the Company issued and sold an aggregate of ~~5,070~~217,038 shares of Common Stock under the ATM Agreement for which the Company received net proceeds of approximately ~~$317,000.~~$7.7 million.

During the ~~six~~nine months ended ~~June~~September 30, 2022, the Company issued an aggregate of 23,086 shares of Common Stock upon the conversion of ~~pre-funded warrants~~the March 2022 Pre-Funded Warrants issued at a par value of ~~$0.01~~$2.10 (See Note 10).

-20-

Table of Contents

During the ~~six~~nine months ended ~~June~~September 30, 2022, the Company issued an aggregate of 910 shares of Common Stock and accompanying Exchange Warrants upon the exchange of an aggregate of 30.92 shares of Series B Preferred Stock with a stated value of approximately $238,000 plus accrued dividends of approximately $27,000. ~~The Exchange Warrants have an exercise price of $264.60 per share and will be exercisable for five years from the issuance date.~~

During the ~~six~~nine months ended ~~June~~September 30, 2022, the Company issued an aggregate of 429 shares of its Common Stock to consultants with a grant date fair value of approximately $119,000 for investor relations services provided, which was recorded as stock-based compensation and included as part of general and administrative ~~expenses.~~expense.

During the nine months ended September 30, 2022, the Company cancelled an aggregate of 12 shares of Common Stock in connection with the 30-for-1 reverse stock split on August 26, 2022.

~~-17-~~

~~Table of Contents~~

Note 10 – Warrants

Warrant activity for the ~~six~~nine months ended ~~June~~September 30, 2023 and 2022 was as follows:


		Weighted		Weighted		Weighted		Weighted
		Average		Average		Average		Average
	Number of	Exercise Price		Remaining	Number of	Exercise Price		Remaining
	Warrants	Per Share		Term in Years	Warrants	Per Share		Term in Years
Outstanding and exercisable on January 1, 2023	2,179,798	$	19.16	5.50	2,179,798	$	19.16	5.50
Issued	6,389,718		1.79	4.85	27,398,790		0.73	4.59
Expired	(116)		773.79	—	(116)		773.79	—
Exercised	(3,048,825)		0.65	4.94	(11,605,861)		0.96	4.72
Warrants outstanding and exercisable on June 30, 2023	5,520,575		7.85	4.86
Warrants outstanding and exercisable on September 30, 2023					17,972,611	$	2.38	4.89

Warrants outstanding and exercisable on January 1, 2022	26,089	$	1,992.90	3.95	26,089	$	1,992.90	3.95
Issued	56,795		161.70	4.67	66,317		142.52	4.49
Expired	(564)		7,755.30	—	(596)		7,880.46	—
Exercised	(23,087)		2.10	4.67	(23,086)		2.10	4.42
Warrants outstanding and exercisable on June 30, 2022	59,233	$	732.90	4.18
Warrants outstanding and exercisable on September 30, 2022					68,724	$	631.33	4.07

The outstanding warrants expire from 2024 through 2028.

During the ~~six~~nine months ended ~~June~~September 30, 2023, the Company issued warrants and pre-funded warrants to purchase 2,941,054 shares of the Company’s Common Stock in connection with the March 2023 ~~Offering. During the six months ended June 30, 2023, the Company issued~~Offering, warrants to purchase 3,448,664 shares of the Company’s Common Stock in connection with the June 2023 Inducement Offering, warrants and pre-funded warrants to purchase 9,245,000 shares of the Company’s Common Stock in connection with the July 2023 Offering, and warrants to purchase 11,764,072 shares of the Company’s Common Stock in connection with the September 2023 Inducement Offering (See Note 9).

During the ~~six~~nine months ended ~~June~~September 30, 2023, an investor exercised pre-funded warrants to purchase ~~1,324,493~~3,999,493 shares of the Company’s Common Stock in connection with previous offerings. During the ~~six~~nine months ended ~~June~~September 30, 2023, an investor exercised warrants to purchase ~~1,724,332~~7,606,368 shares of the Company’s Common Stock in connection with previous offerings as a result of the June 2023 and September 2023 Inducement ~~Offering~~Offerings (see Note 9).

During the ~~six~~nine months ended ~~June~~September 30, 2022, the Company issued warrants, pre-funded warrants, and placement agent warrants to purchase ~~55,883~~55,885 shares of the Company’s Common Stock in connection with the March 2022 Offering, ~~as well as~~ Series C warrants to purchase ~~499~~910 shares of the Company’s Common Stock in connection with a Series B Preferred Stock exchange, ~~(See~~as well as July 2022 Warrants to purchase 9,522 shares of Common Stock in connection with the July 2022 Offering (see Note 9).

During the ~~six~~nine months ended ~~June~~September 30, 2022, an investor exercised pre-funded warrants to purchase ~~23,087~~23,086 shares of the Company’s Common Stock in connection with previous offerings.

-21-

Table of Contents

In connection with the March 2022 Offering, the Company entered into a warrant amendment agreement with an investor pursuant to which the Company agreed to amend the investor’s existing warrants to purchase up to 5,080 shares of Common Stock at an exercise price of ~~$1,680.00~~$1,680 per share issued in January 2021 and warrants to purchase up to 1,872 shares of Common Stock at an exercise price of ~~$2,541.00~~$2,541 per share issued in March 2021 (the “March Existing Warrants”), in consideration for such investor’s purchase of $9.0 million of securities in the March 2022 Offering and payment of $5.901 per share for each share of Common Stock issuable upon exercise of the March Existing Warrants to (i) lower the exercise price of the March Existing Warrants to $264.60 per share and (ii) extend the termination date of the March Existing Warrants to March 2, 2027.

Note 11 – Equity Incentive Plan

The Company’s Board and stockholders adopted and approved the Amended and Restated 2014 Omnibus Equity Incentive Plan (the “2014 Plan”), which took effect on May 12, 2014. The Company’s Board and stockholders adopted and approved the 2020 Omnibus Equity Incentive Plan (the “2020 Plan”), which took effect on September 11, 2020. From the adoption and approval of the 2020 Plan, no new awards have been or will be made under the 2014 Plan.

~~-18-~~

~~Table of Contents~~

The 2020 Plan allows for the issuance of securities, including stock options to employees, Board members and consultants. The initial number of shares of Common Stock available for issuance under the 2020 Plan was 4,761 shares, which will, on January 1 of each calendar year, unless the Board decides otherwise, automatically increase to equal ten percent (10)% of the total number of shares of Common Stock outstanding on December 31 of the immediately preceding calendar year, calculated on an As Converted Basis. As Converted Shares include all outstanding shares of Common Stock and all shares of Common Stock issuable upon the conversion of outstanding preferred stock, warrants and other convertible securities, but will not include any shares of Common Stock issuable upon the exercise of options and other convertible securities issued pursuant to either the 2014 Plan or the 2020 Plan. The number of shares permitted to be issued as “incentive stock options” (“ISOs”) is 7,142 under the 2020 Plan.

On April 20, 2023, the Company’s board of directors approved an amendment (i) increasing the number of shares of Common Stock available for issuance under the 2020 Plan from 317,480 to 1,167,480 and (ii) increasing the number of shares of our Common Stock otherwise available under the 2020 Plan that may be granted as ISOs to 5,000,000 shares. The board of directors directed that the amendment be submitted to the stockholders of the Company at the Company’s annual meeting of stockholders. On June 22, 2023, the stockholders approved the amendment to the 2020 Plan at the annual meeting of stockholders.

As of January 1, 2023, the number of shares of Common Stock available for issuance under the 2020 Plan automatically increased to 317,480 under the 2020 Plan’s evergreen provision.

As of June 22, 2023, as a result of approval at the annual shareholders’ meeting, the number of shares of Common Stock available for issuance under the 2020 Plan increased to 1,167,480.

As of ~~June~~September 30, 2023, there were an aggregate of 1,024 total shares available (but un-issuable) under the 2014 Plan, of which 732 are issued and outstanding, and 292 shares are reserved subject to issuance of restricted stock and RSUs.

As of ~~June~~September 30, 2023, 1,167,480 total shares were authorized under the 2020 Plan, of which ~~159,384~~158,313 were issued and outstanding and ~~1,008,096~~1,009,167 shares were available for potential issuances.

~~During the six months ended June 30, 2023 and 2022, stock option activity under the 2014 Plan and 2020 Plan was as follows:~~

Average

Remaining

Number

Exercise

Contract

Intrinsic


of Shares

Price

Life (Years)

Value
Outstanding at January 1, 2023

4,076

$
958.14

8.22

$
—
Granted

5,000

3.73

9.91

—
Forfeited

(11)

573.68

—

—
Expired

(109)

4,363.67

—

—
Outstanding at June 30, 2023

8,956

$
397.33

8.93

$
—
Exercisable at June 30, 2023

5,271

$
574.49

8.69

$
—

Outstanding at January 1, 2022

1,941

$
2,470.99

7.28

$
—
Granted

3,219

291.90

8.08

—
Cancelled

(202)

278.14

—

—
Forfeited

(475)

852.60

—

—
Outstanding at June 30, 2022

4,483

$
1,096.20

8.52

$
—
Exercisable at June 30, 2022

2,093

$
2,226.00

7.59

$
—

During the six months ended June 30, 2023 and 2022, the Board approved the grant of options to purchase 5,000 and 3,219 shares of Common Stock, respectively. All option grants were pursuant to the 2020 Plan. In general, options granted under the 2020 Plan vest monthly over a 36~~-month period.~~

During the six months ended June 30, 2023 and 2022, stock options to purchase 11 and 475 shares of Common Stock, respectively, were forfeited. During the six months ended June 30, 2023, stock options to purchase 109 shares of Common Stock expired. During the six months ended June 30, 2022, stock options to purchase 202 shares of Common Stock were cancelled.

~~-19-~~-22-

Table of Contents

During the nine months ended September 30, 2023 and 2022, stock option activity under the 2014 Plan and 2020 Plan was as follows:


		Average		Remaining
	Number	Exercise		Contract	Intrinsic
	of Shares	Price		Life (Years)	Value
Outstanding at January 1, 2023	4,076	$	958.14	8.22	$	—
Granted	5,000		3.73	9.40		—
Forfeited	(11)		573.68	—		—
Expired	(109)		4,363.67	—		—
Outstanding at September 30, 2023	8,956	$	397.33	8.68	$	—
Exercisable at September 30, 2023	6,625	$	464.22	8.62	$	—

Outstanding at January 1, 2022	1,941	$	2,470.99	7.28	$	—
Granted	3,266		288.19	7.50		—
Forfeited	(678)		841.40	—		—
Cancelled	(535)		2,485.98	—		—
Outstanding at September 30, 2022	3,994	$	970.41	8.45	$	—
Exercisable at September 30, 2022	1,962	$	1,509.13	7.75	$	—

During the nine months ended September 30, 2023 and 2022, the Board approved the grant of options to purchase 5,000 and 3,266 shares of Common Stock, respectively. All option grants were pursuant to the 2020 Plan. In general, options granted under the 2020 Plan vest monthly over a 36-month period.

During the nine months ended September 30, 2023 and 2022, stock options to purchase 11 and 678 shares of Common Stock, respectively, were forfeited. During the nine months ended September 30, 2023, stock options to purchase 109 shares of Common Stock expired. During the nine months ended September 30, 2022, stock options to purchase 535 shares of Common Stock were cancelled.

For the ~~six~~nine months ended ~~June~~September 30, 2023 and 2022, the fair value of each option grant has been estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:


	2023		2022
Contractual term (in years)	6.50		6.50
Expected Volatility	98.80	%	90.92	%
Risk-free interest rate	4.08	%	1.11	%
Expected Dividend yield	0	%	0	%

Using the Black-Scholes ~~option-pricing model,~~Option Pricing Model, the estimated weighted average fair value of an option to purchase one share of ~~Common Stock~~common stock granted during the ~~six~~nine months ended ~~June~~September 30, 2023 and 2022 was $3.05 and ~~$258.30,~~$223.72, respectively.

Restricted Stock and Restricted Stock Units

Restricted stock refers to shares of Common Stock subject to vesting based on certain service, performance, and market conditions. Restricted stock units (“RSUs”) refer to an award which constitutes a promise to grant shares of Common Stock at the end of a specified restriction period.

As of ~~June~~September 30, 2023 and 2022, under the 2014 Plan, the Company had 130 shares of restricted stock outstanding and an aggregate unrecognized restricted Common Stock expense of approximately $388,000, which will be recognized when vesting of certain milestones become probable.

-23-

Table of Contents

During the ~~six~~nine months ended ~~June~~September 30, 2023, RSU activity under the 2020 Plan was as follows:


		Weighted-Average		Weighted-Average		Weighted-Average		Weighted-Average
	Number	Grant Date		Remaining Recognition	Number	Grant Date		Remaining Recognition
	of Shares	Fair Value		Period (Years)	of Shares	Fair Value		Period (Years)
Non-vested Outstanding at January 1, 2023	—	$	—	—	—	$	—	—
Awarded	160,239		6.20		160,239		6.20
Vested	(77,095)		6.20		(113,595)		6.20
Cancelled	(9,079)		6.20		(10,150)		6.20
Non-vested Outstanding at June 30, 2023	74,065	$	6.20	0.50
Non-vested Outstanding at September 30, 2023					36,494	$	6.20	0.25

During the ~~six~~nine months ended ~~June~~September 30, 2023, the Board approved the grant of 160,239 RSUs. All grants of RSUs were pursuant to the 2020 Plan, vest quarterly over a one-year period and are issued in the following quarter. During the nine months ended September 30, 2023, 113,595 RSUs vested, of which 36,500 were issued in October 2023.

The total stock-based compensation expense for employees and non-employees is included in the accompanying condensed consolidated statements of operations and as follows:


	Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022		2023		2022		2023		2022
Research and development	$	38,165	$	24,839	$	76,245	$	71,246	$	34,847	$	22,623	$	111,092	$	93,870
General and administrative		254,539		350,068		574,775		521,891		228,483		69,018		803,258		590,908
Total stock-based compensation expense	$	292,704	$	374,907	$	651,020	$	593,136	$	263,330	$	91,641	$	914,350	$	684,778

As of ~~June~~September 30, 2023, the Company had unrecognized stock-based compensation expense related to stock options and RSUs of approximately ~~$0.8~~$0.6 million. Approximately ~~$0.6~~$0.4 million of this unrecognized expense will be recognized over the average remaining vesting term of the stock awards of ~~0.78~~0.66 years. Approximately $0.2 million of this unrecognized expense will vest upon achieving certain clinical and/or corporate milestones. The Company will recognize the expense related to these milestones when the milestones become probable.

As of ~~June~~September 30, 2022, the Company had unrecognized stock-based compensation expense of approximately ~~$1.1~~$0.9 million. Approximately ~~$0.6~~$0.4 million of this unrecognized expense will be recognized over the average remaining vesting term of the stock options of ~~9.40~~8.44 years. Approximately $0.5 million of this unrecognized expense will vest upon achieving certain clinical and/or corporate milestones. The Company will recognize the expense related to these milestones when the milestones become probable.

Note 12 – Agreements

License Agreement with Sanofi

On September 13, 2023, the Company entered into a License Agreement with Sanofi, pursuant to which the Company received a license to obtain certain exclusive worldwide rights to develop and commercialize Capeserod, a selective 5-HT4 receptor partial agonist which the Company intends to repurpose and develop for gastrointestinal indications.

The Company paid Sanofi an upfront payment of $500,000 in October 2023 and Sanofi will be eligible to receive up to $46 million in potential development and regulatory milestone payments and up to $235 million in potential commercial milestone payments. Sanofi will also be eligible to receive mid-to-high single-digit royalties on net sales, as well as a percentage of sublicense and transfer revenues with respect to Capeserod. Sanofi will also have a right of first refusal with respect to Capeserod out-licensing transactions.

The upfront payment of $500,000 was recorded as research and development expense in the three and nine months ended September 30, 2023. Depending on the status of development at the time a contingent payment is recognized, the Company may determine that the payment should be expensed as research and development or be capitalized as an intangible asset. This determination will be based on the facts and circumstances that exist at the time a contingent payment is recognized.

~~-20-~~-24-

Table of Contents

The License Agreement shall expire on a country-by-country basis upon the later of: (i) the expiration of the last to expire valid claim of an applicable patent in such country covering such licensed product, (ii) the expiration of the regulatory exclusivity for such licensed product in the applicable country and (iii) the tenth anniversary of the date of first commercial sale of a licensed product in such country. Each party may terminate the License Agreement if the other party materially breaches its obligations under the License Agreement and fails to cure such material breach within 60 days from the date of such notice of breach, except in the case of payment breach, as to which the breaching party will have only a ten-day cure period. Sanofi may terminate the License Agreement upon any bankruptcy proceedings by the Company. The Company may terminate the License Agreement by providing Sanofi with at least 60 days prior written notice; provided, however, that Sanofi shall be entitled to any and all payments due and owed to Sanofi prior to the effective date of termination.

Note 12 13 – Leases

The Company leases its office under an operating lease which is subject to various rent provisions and escalation clauses.

The Company is a party to one real property operating lease for the rental of office space. The Company has office space of 3,472 square feet in Boca Raton, Florida that is used for its corporate headquarters with a term through August 31, 2026. The Company previously had office space in Brooklyn, New York on a month-to-month basis, which was terminated in June 2023. The Company was also previously a party to office space in Hayward, California with a term through May 31, 2022, which was not renewed upon its expiration.

The Company’s lease expires in 2026. The escalation clause is indeterminable and considered not material and has been excluded from minimum future annual rental payments.

Lease ~~expenses were~~expense was approximately ~~$35,000~~$42,000 and ~~$50,000,~~$36,000, respectively, for the three months ended ~~June~~September 30, 2023 and 2022 and ~~$72,000~~$114,000 and ~~$78,000,~~$115,000, respectively, for the ~~six~~nine months ended ~~June~~September 30, 2023 and 2022.

The weighted-average remaining lease term and weighted-average discount rate under operating leases as of ~~June~~September 30, 2023 are:


	~~June~~September 30,
	2023
Lease term and discount rate	2.9
Weighted-average remaining lease term (years)	~~3.2~~
Weighted-average discount rate	7.00	%

Maturities of operating lease liabilities as of ~~June~~September 30, 2023, were as follows:


2023 (remainder of year)	$	42,360	$	42,360
2024		86,202		86,202
2025		88,788		88,788
2026		60,593		60,593
Total lease payments		277,943		277,943
Less imputed interest		(29,717)		(46,651)
Present value of lease liabilities	$	248,226	$	231,292

Note 1314 - Net ~~Loss~~(Loss) Income per Common Share

Basic net loss per share is computed by dividing net loss available to Common Stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not deemed to be anti-dilutive. The dilutive effect of the outstanding stock options and warrants is computed using the treasury stock method.

-25-

Table of Contents

All shares of Common Stock that may potentially be issued in the future are as follows:

June 30, 2023

June 30, 2022

(unaudited)

(unaudited)
Common stock warrants

5,520,575

59,233
Stock options

8,956

4,483
RSUs not yet issued

160,239

—
Convertible preferred stock (1)

3,157

3,416
Restricted stock not yet issued

162

162
Total shares of Common Stock issuable

5,693,089

67,294


	Three Months Ended				Nine Months Ended
	September 30, 2023		September 30, 2022		September 30, 2023		September 30, 2022
Net (loss) income applicable to common shareholders	$	(3,483,450)	$	4,233,753	$	(11,925,090)	$	(10,989,148)

Basic weighted average shares outstanding		7,566,018		228,773		3,763,506		136,113
Convertible preferred stock		—		3,475		—		—
Diluted weighted average shares outstanding		7,566,018		232,248		3,763,506		136,113
Basic net (loss) income per share	$	(0.46)	$	18.51	$	(3.17)	$	(80.74)
Diluted net (loss) income per share	$	(0.46)	$	18.23	$	(3.17)	$	(80.74)

All shares of Common Stock that may potentially be issued in the future are as follows:


	September 30, 2023	September 30, 2022
	(unaudited)	(unaudited)
Common stock warrants	17,972,611	68,724
Stock options	8,956	3,994
RSUs not yet issued	72,994	—
Convertible preferred stock (1)	3,084	3,475
Restricted stock not yet issued	162	162
Total shares of common stock issuable	18,057,807	76,355

(1)	Convertible preferred stock is assumed to be converted at the rate of ~~$1,617.70~~$1,617 per common share, which is the conversion price as of ~~June~~September 30, 2023.

~~-21-~~

~~Table of Contents~~

Note 1415 - Employee Benefit Plans

401(k) Plan

Since 2015, the Company has sponsored a multiple employer defined contribution benefit plan, which complies with Section 401(k) of the Internal Revenue Code covering substantially all employees of the Company. All employees are eligible to participate in the plan. Employees may contribute from 1% to 100% of their compensation and the Company matches an amount equal to 100% on the first 6% of the employee contribution and may also make discretionary profit-sharing contributions.

Employer contributions under this 401(k) plan amounted to approximately $21,000 ~~and $29,000~~ for each of the three months ended ~~June~~September 30, 2023 and 2022, ~~respectively,~~ and approximately ~~$47,000~~$68,000 and ~~$76,000~~$97,000 for the ~~six~~nine months ended ~~June~~September 30, 2023 and 2022, respectively.

Note 1516 - Subsequent ~~Events~~Event

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were available to be issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements except for the ~~items~~item noted below.

~~Phase 2 SPAN Trial~~

On ~~July 13,~~October 26, 2023, the Company ~~announced initial topline results~~received a notice from the ~~Phase 2b SPAN clinical trial investigating~~Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that in connection with the July 2023 Offering, the Company was not in compliance with Nasdaq’s shareholder approval requirements set forth in listing rule 5635(d), which requires prior shareholder approval for transactions, other than public offerings, involving the issuance of 20% or more of the pre-transaction shares outstanding at less than the Minimum Price. The Company has 45 calendar days to submit a plan to regain compliance. If the plan is accepted, the Staff can grant an ~~enhanced enteric microgranule delivery formulation~~extension of ~~adrulipase for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. Initial data~~up to 180 calendar days from the ~~study indicated that~~date of the enhanced adrulipase formulation was safe and well tolerated, as well as demonstrated an improvement over prior formulations of adrulipase. However, the preliminary data also indicated that it is likely that the primary efficacy endpoint was not achieved. The Company is continuingletter to ~~assess the data and expects to report additional findings on primary and secondary endpoints in the third quarter of 2023.~~

~~July 2023 Public Offering~~

~~On July 21, 2023, the Company completed a public offering (the “~~~~July 2023 Offering~~~~”) for an aggregate of (i) 610,000 shares of Common Stock, (ii) pre-funded warrants (the “~~~~July 2023 Pre-Funded Warrants~~~~”) to purchase up to an aggregate of 2,675,000 shares of Common Stock, and (iii) common warrants (the “~~~~July 2023 Warrants~~”) to purchase up to an aggregate of 6,570,000 shares of Common Stock. The public offering price for each share of Common Stock and accompanying July 2023 Warrant to purchase one share of Common Stock was $0.64 per share. The July 2023 Pre-Funded Warrants have an exercise price of $0.0001 per share, are exercisable immediately and will expire when exercised in full. To date, pre-funded warrants have been exercised to purchase 2,246,000 shares of Common Stock. The July 2023 Warrants have an exercise price of $0.64 per share, are exercisable immediately and will expire five years from the initial exercise date.

~~The Company received gross proceeds of approximately $2.1 million less placement agent’s fees and other offering expenses of approximately $350,000.~~

evidence compliance.

~~-22-~~-26-

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

References in this report to “First Wave,” “AzurRx,” “Company,” “we,” “us,” “our,” or similar references mean First Wave BioPharma, Inc. and its subsidiaries on a consolidated basis. References to “First Wave BioPharma” refer to First Wave BioPharma, Inc. on an unconsolidated basis. References to “AzurRx SAS” refer to First Wave BioPharma’s former wholly owned subsidiary through which we previously conducted our European operations. References to the “SEC” refer to the U.S. Securities and Exchange Commission.

Forward-Looking Statements

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and the related notes included elsewhere in this interim report. Our consolidated financial statements have been prepared in accordance with U.S. GAAP. The following discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including, without limitation, statements regarding our expectations, beliefs, intentions or future strategies that are signified by the words “expect,” “anticipate,” “intend,” “believe,” or similar language. All forward-looking statements included in this document are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. Our business and financial performance are subject to substantial risks and uncertainties. Actual results could differ materially from those projected in the forward-looking statements. In evaluating our business, you should carefully consider the information set forth under the heading “Risk Factors” included in our Annual Report filed on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 20, 2023. Readers are cautioned not to place undue reliance on these forward-looking statements.

Overview

We are engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (“GI”) diseases. Non-systemic therapies are non-absorbable drugs that act locally, i.e., in the intestinal lumen, skin or mucosa, without reaching an individual’s systemic circulation.

We are currently focused on developing ~~our~~a therapeutic pipeline ~~of gut-restricted GI~~with multiple Phase 2 clinical ~~drug candidates, including the~~stage programs built around three proprietary technologies –the biologic ~~adrulipase (formerly MS1819),~~Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and ~~niclosamide,~~chronic pancreatitis patients with exocrine pancreatic insufficiency; Capeserod, a selective 5-HT4 receptor partial agonist which we will pursue for GI indications; and Niclosamide, an oral small molecule with ~~anti-viral~~anti-inflammatory properties for patients with inflammatory bowel diseases such as ulcerative colitis and ~~anti-inflammatory properties.~~Crohn’s disease.

Our ~~adrulipase~~Adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”) and chronic pancreatitis (“CP”). Our goal is to provide CF and CP patients with a safe and effective therapy to control EPI that is non-animal derived and offers the potential to dramatically reduce their daily pill burden. In ~~March 2021,~~July 2023, we announced topline results from our Phase 2b ~~OPTION 2~~ monotherapy ~~trial, and in 2021, we announced positive topline results from our Phase 2 Combination trial in Europe. In November 2022 we filed a Phase 2b investigational new drug (“~~~~IND~~~~”) amendment for a~~ bridging study using a new enteric microgranule formulation of ~~adrulipase with the U.S. Food and Drug Administration (“~~~~FDA~~~~”). We initiated the Phase 2b monotherapy trial during the first quarter of 2023 and announced initial topline data in July 2023.~~Adrulipase While the initial data from the study indicated that the enhanced ~~adrulipase~~Adrulipase formulation was safe and well tolerated and demonstrated an improvement over prior formulations of ~~adrulipase,~~Adrulipase, it also indicated that it is likely that the primary efficacy endpoint was not achieved. We are continuing to assess this data, along with secondary efficacy endpoint data, and plan to schedule a Type C meeting with the ~~data~~FDA in 2024 to discuss next steps for the Adrulipase program.

Our Capeserod program was in-licensed from Sanofi in September 2023. Sanofi conducted Phase 1 and Phase 2 Central Nervous System (“CNS”) trials with over 600 patients. In Sanofi’s Phase 1 CNS trial, Capeserod appeared safe and well-tolerated. Research on Capeserod and subsequent artificial intelligence (“AI”) empowered analyses suggest that the drug possesses a unique mechanism of action that is applicable to several GI indications underserved by currently available therapeutics. We plan to repurpose Capeserod for GI indications and expect to ~~report additional findings on primary~~initiate a Phase 2 clinical development program in either pediatric ulcerative colitis or gastroparesis. Sanofi retains the right of first refusal to develop and ~~secondary endpoints in the third quarter~~commercialize Capeserod.

-27-

Table of ~~2023.~~Contents

Our ~~niclosamide~~Niclosamide programs leverage proprietary oral and topical formulations to address multiple GI conditions, including inflammatory bowel diseases (“IBD”) indications. In 2022 we advanced two separate Phase 2 clinical programs of our ~~niclosamide~~Niclosamide formulations, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 (“COVID-19”) GI infections, and FW-UP for ulcerative proctitis (“UP”) and ulcerative proctosigmoiditis (“UPS”).

~~-23-~~

~~Table of Contents~~

We announced the completion of enrollment in the FW-COV trial in January 2022 and topline results in August 2022. In September 2022 we announced that we would no longer pursue the anti-viral COVID-GI clinical indication as a result of the mixed results from the FW-COVID-19 trial. Additionally, we are devoting fewer resources to the FW-UP/UPS ~~niclosamide~~Niclosamide program due to inconclusive data from a small Phase 2 trial in Europe, the need for a new FDA-IND cleared protocol, and financial constraints.

We are further developing FW-ICI-AC for Immune Checkpoint Inhibitor-associated colitis (“ICI-AC”) and diarrhea in advanced stage oncology patients, which received FDA IND clearance for a Phase 2a clinical trial in October 2021, and two pre-IND programs of our ~~niclosamide~~Niclosamide therapies for additional IBD indications, including FW-UC for ulcerative colitis (“UC”) and FW-CD for Crohn’s disease (“CD”). However, the FW-ICI-AC program is currently on hold due to financial constraints.

Nasdaq Continued Listing Requirements

On August 17, 2023, we received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that we were not in compliance with the $2.5 million minimum stockholders’ equity requirement for continued listing of our common stock on Nasdaq as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Minimum Stockholder’s Equity Rule”). In that regard, we reported stockholders’ equity of $881,960 in our Quarterly Report on Form 10-Q for the period ended June 30, 2023 (we did not then, and do not now, meet the alternative compliance standards relating to the market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years). On October 2, 2023, we submitted a plan to the Staff to regain compliance with the Minimum Stockholders’ Equity Rule. If our plan is accepted, the Staff can grant an extension of up to 180 calendar days from the date of the letter to evidence compliance. We are awaiting a determination from the Staff regarding our request for an extension to regain compliance.

On August 24, 2023, we received notice from the Staff indicating that, based upon the closing bid price of our common stock for the prior 30 consecutive business days, we were not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). We have 180 days from August 24, 2023, or through February 20, 2024, to regain compliance with the Bid Price Rule.

On October 26, 2023, we received a notice from the Staff indicating that in connection with our July 2023 Offering, we were not in compliance with Nasdaq’s shareholder approval requirements set forth in listing rule 5635(d), which requires prior shareholder approval for transactions, other than public offerings, involving the issuance of 20% or more of the pre-transaction shares outstanding at less than the Minimum Price. We have 45 calendar days to submit a plan to regain compliance. If our plan is accepted, the Staff can grant an extension of up to 180 calendar days from the date of the letter to evidence compliance.

Liquidity and Capital Resources

To date, we have not generated any revenues and have experienced net losses and negative cash flows from our activities.

As of ~~June~~September 30, 2023, we had cash and cash equivalents of approximately ~~$1.2~~$3.3 million, and had sustained cumulative losses attributable to common stockholders of approximately ~~$176.8~~$180.2 million. ~~Subsequent to June 30, 2023 through August 14, 2023, we have raised aggregate gross proceeds of approximately $2.1 million from the July 2023 Offering.~~ We anticipate having sufficient cash to fund planned operations through ~~September~~December 2023, however, the acceleration or reduction of cash outflows by management can significantly impact the timing for the need to raise additional capital to complete development of our products. We have not yet achieved profitability and anticipate that we will continue to incur net losses for the foreseeable future. We expect that our expenses will continue to grow and, as a result, we will need to generate significant product revenues to achieve profitability. We may never achieve profitability. As such, we are dependent on obtaining, and are continuing to pursue, the necessary funding from outside sources, including obtaining additional funding from the sale of securities in order to continue our operations. Without adequate funding, we may not be able to meet our obligations. We believe these conditions may raise substantial doubt about our ability to continue as a going concern.

-28-

Table of Contents

We have funded our operations to date primarily through the issuance of debt, convertible debt securities, preferred stock, as well as the issuance of Common Stock in various public offerings and private placement transactions. We expect to incur substantial expenditures in the foreseeable future for the development of ~~adrulipase, niclosamide~~Adrulipase, Capeserod, Niclosamide and any other drug candidates. We will require additional financing to develop our drug candidates, run clinical trials, prepare regulatory filings and obtain regulatory approvals, fund operating losses, and, if deemed appropriate, establish manufacturing, sales and marketing capabilities. Our current financial condition raises substantial doubt about our ability to continue as a going concern. Our failure to raise capital as and when needed would have a material adverse impact on our financial condition, our ability to meet our obligations, and our ability to pursue our business strategies. We will seek funds through additional equity and/or debt financings, collaborative or other arrangements with corporate sources, or through other sources of financing.

Although, we are primarily focused on the development of our drug candidates, including ~~adrulipase~~Adrulipase, Capeserod, and ~~niclosamide,~~Niclosamide, we are also opportunely focused on expanding our product pipeline of clinical assets through collaborations, and also through acquisitions of products and companies. We are continually evaluating potential asset acquisitions business combinations, and other partnership opportunities. To finance such acquisitions, we might raise additional equity capital, incur additional debt, or both.

We are able to sell securities on a shelf registration statement pursuant to the ATM Agreement with H.C. Wainwright & Co., LLC. Under current SEC regulations, because our public float was less than $75 million at the relevant measurement period pursuant to General Instruction I.B.6. to Form S-3, the amount we can raise through primary public offerings of securities in any subsequent twelve-month period under our shelf registration statement is limited to an aggregate of one-third of our public float until such time, if any, as our public float is $75 million or more. As a result, we are currently restricted from using the ATM Agreement.

Our ability to issue securities is subject to market conditions. Each issuance under ~~the~~a shelf registration ~~statements~~statement will require the filing of a prospectus supplement identifying the amount and terms of the securities to be issued.

~~-24-~~

~~Table of Contents~~

Consolidated Results of Operations for the Three Months Ended ~~June~~September 30, 2023 and 2022

The following table summarizes our consolidated results of operations for the periods indicated:


	Three Months Ended						Three Months Ended
	June 30,				Increase		September 30,				Increase
	2023		2022		(decrease)		2023		2022		(decrease)
Operating expenses:
Research and development expenses	$	1,353,095	$	2,906,896	$	(1,553,801)	$	1,011,055	$	791,067	$	219,988
Research and development recovery - intellectual property acquired								—		(8,085,045)		(8,085,045)
General and administrative expenses		2,828,549		2,498,957		329,592		2,422,082		2,904,448		(482,366)
Total operating expenses		4,181,644		5,405,853		(1,224,209)
Other expenses		7,588		2,292		5,296
Net loss	$	4,189,232	$	5,408,145	$	(1,218,913)
Total operating expenses (recovery)								3,433,137		(4,389,530)		7,822,667
Other expenses (income)								1,021		(1,801)		2,822
Net loss (income)							$	3,434,158	$	(4,391,331)	$	7,825,489

Research and Development Expenses

Research and development expenses include expenses primarily relating to the development of our ~~adrulipase~~Adrulipase, Capeserod and ~~niclosamide~~Niclosamide drug candidates.

Research and development expenses for the three months ended ~~June~~September 30, 2023 totaled approximately ~~$1.4~~$1.0 million, ~~a decrease~~an increase of approximately ~~$1.5~~$0.2 million, or ~~53%~~28%, over the approximately ~~$2.9~~$0.8 million ~~recorded~~ for the three months ended ~~June~~September 30, 2022.

The ~~decrease~~increase in research and development expenses was primarily attributable to ~~decreases~~the up-front payment of ~~approximately $0.6~~$0.5 million due to Sanofi recorded in ~~clinical related expenses in connection with our Phase 2b adrulipase SPAN clinical trial during~~ the three months ended ~~June~~September 30, 2023 ~~as compared to our Phase 2 RESERVOIR COVID-19 GI clinical trial during~~per the ~~three months ended June 30, 2022,~~executed license agreement for Capeserod. This increase was partially offset by decreases of approximately ~~$0.6~~$0.2 million in personnel related costs and approximately $0.1 million in manufacturing costs related to ~~adrulipase,~~Adrulipase.

Research and development recovery, related to intellectual property acquired, for the three months ended September 30, 2023, totaled $0 million as ~~well as~~compared to $8.1 million for the three months ended September 30, 2022. This decrease was due to the liability reduction recorded in the three months ended September 30, 2022 of approximately ~~$0.3~~$8.1 million in ~~personnel related costs.~~accordance with the July 2022 Term Sheet with Fortis Advisors LLC.

-29-

Table of Contents

We expect research and development expenses to decrease during the remainder of this fiscal year as we close out the Phase 2b ~~adrulipase~~Adrulipase SPAN clinical trial.

General and Administrative Expenses

General and administrative expenses include expenses primarily relating to our overall operations and being a public company, including personnel, legal and financial professional services, insurance, corporate communication and investor relations, listing and compliance related costs, rent, and expenses associated with obtaining and maintaining intellectual property and patents, among others.

General and administrative expenses for the three months ended ~~June~~September 30, 2023 totaled approximately ~~$2.8~~$2.4 million, ~~an increase~~a decrease of approximately ~~$0.3~~$0.5 million, or ~~13%~~17% over the approximately ~~$2.5~~$2.9 million recorded for the three months ended ~~June~~September 30, 2022.

The ~~increase~~decrease in general and administrative expenses was primarily due to ~~increases~~decreases of approximately ~~$0.6~~$0.5 million in public company costs, including investor relations and corporate ~~communications, partially offset by decreases of~~communications; and approximately $0.3 million in professional fees, including audit and ~~other corporate~~legal expenses; partially offset by an increase of approximately $0.3 million in non-cash stock-based compensation costs.

We expect general and administrative expenses to remain stable during the remainder of this fiscal year.

Other Expenses

Other expenses for the three months ended ~~June~~September 30, 2023 ~~totaled approximately $7,600, an increase of approximately $5,300, or 231% over the approximately $2,300 of~~were essentially flat with other expenses recorded for the three months ended ~~June~~September 30, 2022. ~~The increase in other expenses was mainly due to higher interest expense.~~

Net Loss (Income)

As a result of the factors above, our net loss for the three months ended ~~June~~September 30, 2023 totaled approximately ~~$4.2~~$3.4 million, ~~a decrease~~an increase of approximately ~~$1.2~~$7.8 million, or ~~23%~~157%, over the approximately ~~$5.4~~$4.4 million net income recorded for the three months ended ~~June~~September 30, 2022.

~~-25-~~

~~Table of Contents~~

Consolidated Results of Operations for the ~~Six~~Nine Months Ended ~~June~~September 30, 2023 and 2022

The following table summarizes our consolidated results of operations for the periods indicated:


	Six Months Ended						Nine Months Ended
	June 30,				Increase		September 30,				Increase
	2023		2022		(decrease)		2023		2022		(decrease)
Operating expenses:
Research and development expenses	$	2,714,778	$	7,883,413	$	(5,168,635)	$	3,725,833	$	8,674,480	$	(4,948,647)
Research and development recovery – intellectual property acquired								—		(8,085,045)		8,085,045
General and administrative expenses		5,529,291		6,904,512		(1,375,221)		7,951,373		9,808,960		(1,857,587)
Total operating expenses		8,244,069		14,787,925		(6,543,856)		11,677,206		10,398,395		1,278,811
Other expenses		15,816		247,059		(231,243)		16,837		245,258		(228,421)
Net loss	$	8,259,885	$	15,034,984	$	(6,775,099)	$	11,694,043	$	10,643,653	$	1,050,390

Research and Development Expenses

Research and development expenses include expenses primarily relating to the development of our ~~adrulipase~~Adrulipase, Capeserod and ~~niclosamide~~Niclosamide drug candidates.

Research and development expenses for the ~~six~~nine months ended ~~June~~September 30, 2023 totaled approximately ~~$2.7~~$3.7 million, a decrease of approximately ~~$5.2~~$4.9 million, or ~~66%~~57%, over the approximately ~~$7.9~~$8.7 million recorded for the ~~six~~nine months ended ~~June~~September 30, 2022.

The decrease in research and development expenses was primarily attributable to decreases of approximately $3.7 million infor clinical related expenses in connection with our Phase 2b ~~adrulipase~~Adrulipase SPAN clinical trial during the ~~six~~nine months ended ~~June~~September 30, 2023, as compared to our Phase 2 RESERVOIR COVID-19 GI clinical trial during the ~~six~~nine months ended ~~June~~September 30, ~~2022,~~2022; approximately ~~$0.8~~$1.0 million in manufacturing costs related to ~~adrulipase, as well as~~Adrulipase; and approximately ~~$0.7~~$0.9 million in personnel related costs. These decreases were partially offset by the up-front payment of $0.5 million due to Sanofi per the executed license agreement for Capeserod.

-30-

Table of Contents

Research and development recovery, related to intellectual property acquired, for the nine months ended September 30, 2023 totaled $0 million as compared to $8.1 million for the nine months ended September 30, 2022. This increase was due to the liability reduction recorded in the nine months ended September 30, 2022 of approximately $8.1 million in accordance with the July 2022 Term Sheet with Fortis Advisors LLC.

We expect research and development expenses to decrease during the remainder of this fiscal year as we work to close out the Phase 2b ~~adrulipase~~Adrulipase SPAN clinical trial.

General and Administrative Expenses

General and administrative expenses for the ~~six~~nine months ended ~~June~~September 30, 2023 totaled approximately ~~$5.5~~$8.0 million, a decrease of approximately ~~$1.4~~$1.9 million, or ~~20%~~19% over the approximately ~~$6.9~~$9.8 million recorded for the ~~six~~nine months ended ~~June~~September 30, 2022.

The decrease in general and administrative expenses was primarily due to decreases of approximately ~~$0.5~~$0.8 million in professional fees, including audit and legal expenses; approximately ~~$0.3 million in personnel related costs, approximately $0.3 million in other corporate costs, and approximately $0.2~~$0.6 million in public company costs, including investor relations and corporate ~~communications.~~communications; and approximately $0.3 million in corporate costs.

We expect general and administrative expenses to remain stable during the remainder of this fiscal year.

Other Expenses

Other expenses for the ~~six~~nine months ended ~~June~~September 30, 2023 ~~totaled approximately $16,000, a decrease of~~decreased approximately $0.2 million, or ~~94%~~93% over the approximately $0.2 million of other expenses recorded for the ~~six~~nine months ended ~~June~~September 30, 2022. The decrease in other expenses was mainly due to the ~~approximately~~ $0.2 million of ~~cash~~Waiver fees paid ~~during~~in the ~~six~~nine months ended ~~June~~September 30, ~~2022 related to the Series B Waiver agreements.~~2023.

~~-26-~~

~~Table of Contents~~

Net Loss

As a result of the factors above, our net loss for the ~~six~~nine months ended ~~June~~September 30, 2023 totaled approximately ~~$8.2~~$11.7 million, ~~a decrease~~an increase of approximately ~~$6.8~~$1.1 million, or ~~45%~~10%, over the approximately ~~$15.0~~$10.6 million recorded for the ~~six~~nine months ended ~~June~~September 30, 2022.

Cash Flows for the ~~Six~~Nine Months Ended ~~June~~September 30, 2023 and 2022

The following table summarizes our cash flows for the periods indicated:


	Six Months Ended				Nine Months Ended
	June 30,				September 30,
	2023		2022		2023		2022
Net cash (used in) provided by:
Net cash provided by (used in):
Operating activities	$	(5,607,262)	$	(12,497,681)	$	(8,438,474)	$	(16,751,790)
Investing activities						(500,000)		—
Financing activities		5,480,412		5,443,522		10,867,899		10,215,292
Net decrease in cash and cash equivalents	$	(126,850)	$	(7,054,159)
Net increase (decrease) in cash, cash equivalents and restricted cash					$	1,929,425	$	(6,536,498)

Operating Activities

Net cash used in operating activities during the ~~six~~nine months ended ~~June~~September 30, 2023 of approximately ~~$5.6~~$8.9 million was primarily attributable to our net loss of approximately ~~$8.2 million,~~$11.7 million; partially offset by a decrease in prepaid expenses of approximately $1.3 million, non-cash expenses of approximately ~~$0.7~~$1.0 million, mainly related to stock-based compensation ~~as well as~~and common stock issued to consultants; and a ~~decrease~~net increase in ~~prepaid~~accrued expenses ~~of $0.9 million~~ and ~~increases in~~ accounts payable ~~and accrued expense~~ of approximately ~~$1.0~~$0.4 million.

-31-

Table of Contents

Net cash used in operating activities during the ~~six~~nine months ended ~~June~~September 30, 2022 of approximately ~~$12.5~~$16.8 million was primarily attributable to our net loss of approximately ~~$15.0~~$10.6 million and the decrease in other liabilities in accordance with the July 2022 Term Sheet of approximately $8.1 million, partially offset by non-cash expenses of approximately ~~$0.8~~$0.9 million, mainly related to ~~Common Stock~~common stock issued to consultants of approximately $0.1 million and stock-based compensation of approximately ~~$0.6~~$0.7 million, as well as increases in accounts payable and accrued expense of approximately ~~$1.3~~$0.8 million and a decrease in prepaid expenses of $0.6 million.

Investing Activities

For the nine months ended September 30, 2023 and 2022, we did not use any cash for investing activities.

Financing Activities

Net cash provided by financing activities of approximately ~~$5.5~~$10.9 million for the ~~six~~nine months ended ~~June~~September 30, 2023 was ~~primarily~~ due to the net proceeds of approximately ~~$2.2~~$5.9 million from the exercise of warrants, ~~and $3.7~~the net proceeds of approximately $5.5 million from the March 2023 ~~Offering,~~and July 2023 offerings of our common stock, partially offset by ~~approximately $0.4 million of cash~~ repayments of approximately $0.6 million related to the note ~~payable financing for corporate insurances.~~payable.

Net cash provided by financing activities of approximately ~~$5.4~~$10.2 million for the ~~six~~nine months ended ~~June~~September 30, 2022 was primarily due to the net proceeds of approximately $8.0 million from the March 2022 ~~Offering~~registered direct offering of our common stock and warrants, the issuance of Common Stock ~~and warrants,~~of approximately $7.7 million from sales made under our ATM offering program, partially offset by approximately ~~$2.4~~$4.9 million of cash payments made related to the Merger Agreement and July 2022 Term Sheet, as well as repayments of approximately ~~$0.5~~$0.6 million related to the note payable.

Critical Accounting Policies and Estimates

Our accounting policies are essential to understanding and interpreting the financial results reported on the consolidated financial statements. The significant accounting policies used in the preparation of our consolidated financial statements are summarized in Note 2 to the consolidated financial statements and notes thereto found in our Annual Report on Form 10-K for the year ended December 31, 2022. Certain of those policies are considered to be particularly important to the presentation of our financial results because they require us to make difficult, complex or subjective judgments, often as a result of matters that are inherently uncertain.

During the ~~six~~nine months ended ~~June~~September 30, 2023, there were no material changes to matters discussed under the heading “Critical Accounting Policies and Significant Judgments and Estimates” in Part II, Item 7 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

~~-27-~~-32-

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

As required by Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) our Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”) conducted an evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on that evaluation, our CEO and our CFO each concluded that our disclosure controls and procedures are effective to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act, (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (ii) is accumulated and communicated to our management, including our CEO and our CFO, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

~~-28-~~-33-

Table of Contents

PART II

OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

On January 27, 2023, David Hoffman, a former member of the Company’s board of directors, filed a complaint in the Court of Chancery of the State of Delaware against the Company seeking advancement of his attorneys’ fees and expenses relating to certain aspects of his service as a director of the Company (the “Complaint”). The Complaint alleges that Mr. Hoffman is entitled to reimbursement of approximately $250,000 of alleged fees and expenses he has purportedly incurred in the lawsuit filed in the Court of Chancery. The case went to trial in May 2023 and the ~~parties are awaiting a decision from~~court found in favor of the ~~court.~~Company in September 2023. Mr. Hoffman ~~may seek advancement of additional fees~~filed a motion to reargue or amend in October 2023 and ~~expenses. If the Company does not prevail,~~ the court ~~may award Mr. Hoffman all or some lesser amount of the amount he is seeking.~~denied this request.

ITEM 1A. RISK FACTORS

~~There have been no material changes~~You should carefully consider the factors discussed in ~~or additions to the risk factors included~~Part I, Item 1A., “Risk Factors” in our Annual Report ~~on Form 10-K~~ for the fiscal year ended December 31, ~~2022.~~2022, which could materially affect our business, financial position, or future results of operations. The risks described in our Annual Report for the fiscal year ended December 31, 2022, are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial position, or future results of operations. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC. The risk factor set forth below supplements and updates the risk factors previously disclosed and should be read together with the risk factors described in our Annual Report for the fiscal year ended December 31, 2022 and with any risk factors we may include in subsequent periodic filings with the SEC.

Our failure to maintain compliance with Nasdaq’s continued listing requirements could result in the delisting of our Common Stock.

Our common stock is currently listed for trading on The Nasdaq Stock Market LLC. We must satisfy the continued listing requirements of Nasdaq, to maintain the listing of our common stock on The Nasdaq Stock Market LLC.

On August 17, 2023, we received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that we were not in compliance with the $2.5 million minimum stockholders’ equity requirement for continued listing of the Common Stock on Nasdaq, as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Rule”). In that regard, we reported a stockholders’ deficit of $(881,960) in our Quarterly Report on Form 10-Q for the period ended June 30, 2023 (we did not then, and do not now, meet the alternative compliance standards relating to the market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years). On October 2, 2023, we submitted a plan to the Staff to regain compliance with the Minimum Stockholders’ Equity Rule.

On October 26, 2023, we received notice from the Staff of Nasdaq indicating that, in connection with our July 2023 Offering, we were not in compliance with Nasdaq’s shareholder approval requirements set forth in Listing Rule 5635(d), which requires prior shareholder approval for transactions, other than public offerings, involving the issuance of 20% or more of the pre-transaction shares outstanding at less than the Minimum Price. We have 45 calendar days to submit a plan to regain compliance. If our plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from the date of the letter to evidence compliance.

There can be no assurance that we will be able to regain and sustain compliance with all applicable requirements for continued listing on The Nasdaq Stock Market LLC. In the event that we are unable to regain and sustain compliance with all applicable requirements for continued listing on the Nasdaq, our common stock may be delisted from Nasdaq.

-34-

Table of Contents

If our common stock were delisted from Nasdaq, trading of our common stock would most likely take place on an over-the-counter market established for unlisted securities, such as the OTCQB or the Pink Market maintained by OTC Markets Group Inc. An investor would likely find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our common stock on an over-the-counter market, and many investors would likely not buy or sell our common stock due to difficulty in accessing over-the-counter markets, policies preventing them from trading in securities not listed on a national exchange or other reasons. In addition, as a delisted security, our common stock would be subject to SEC rules as a “penny stock,” which impose additional disclosure requirements on broker-dealers. The regulations relating to penny stocks, coupled with the typically higher cost per trade to the investor of penny stocks due to factors such as broker commissions generally representing a higher percentage of the price of a penny stock than of a higher-priced stock, would further limit the ability of investors to trade in our common stock. In addition, delisting would materially and adversely affect our ability to raise capital on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities. For these reasons and others, delisting would adversely affect the liquidity, trading volume and price of our common stock, causing the value of an investment in us to decrease and having an adverse effect on our business, financial condition and results of operations, including our ability to attract and retain qualified employees and to raise capital.

If we breach our license or other intellectual property-related agreements for our product candidates or otherwise experience disruptions to our business relationships with our licensor, we could lose the ability to continue the development and commercialization of our product candidates.

On September 13, 2023, we entered into a license agreement with Sanofi (the “Sanofi License Agreement”), pursuant to which we received a license to obtain certain exclusive worldwide rights to develop and commercialize Capeserod, a selective 5-HT4 receptor partial agonist which we intend to repurpose and develop for gastrointestinal indications. Our license may not cover all intellectual property rights owned or controlled by our licensor and relevant to our product candidates. If we have not obtained a license to all intellectual property rights owned or controlled by our licensor that are relevant to our product candidates, we may need to obtain additional licenses to such intellectual property rights which may not be available on an exclusive basis, on commercially reasonable terms or at all. In addition, if our licensor breaches such agreement, we may not be able to enforce such agreements against our licensor or their parent entity or affiliates. Under the Sanofi License Agreement, in exchange for licensing to us the right to develop and commercialize the applicable product candidate, Sanofi will be eligible to receive from us milestone payments, tiered royalties from commercial sales of such product candidates, assuming relevant approvals from government authorities are obtained, or other payments.

If we fail to meet any of our obligations under our license and intellectual property-related agreements, our licensors may have the right to terminate our licenses and sublicenses and, upon the effective date of such termination, have the right to re-obtain the licensed and sublicensed technology and intellectual property. If any of our licensors terminate any of our licenses or sublicenses, we will lose the right to develop and commercialize our applicable product candidates and other third parties may be able to market product candidates similar or identical to ours. In such case, we may be required to provide a grant back license to the licensors under our own intellectual property with respect to the terminated products. While we would expect to exercise all rights and remedies available to us, including seeking to cure any breach by us, and otherwise seek to preserve the intellectual property rights licensed and sublicensed to us, we may not be able to do so in a timely manner, at an acceptable cost or at all. In particular, some of the milestone payments are payable upon our product candidates reaching development milestones before we have commercialized, or received any revenue from, sales of such product candidate, and we cannot guarantee that we will have sufficient resources to make such milestone payments. Any uncured, material breach under the license agreements could result in our loss of exclusive rights and may lead to a complete termination of our rights to the applicable product candidate. Any of the foregoing could have a material adverse effect on our business, financial conditions, results of operations and prospects.

In addition, disputes may further arise regarding intellectual property subject to a license agreement, including, but not limited to:

●

the scope of rights granted under the license agreement and other interpretation-related issues;

●

the extent to which our technology and processes infringe, misappropriate or otherwise violate intellectual property of the licensor that is not subject to the licensing agreement;

●

the sublicensing of patent and other rights under our collaborative development relationships;

●

our diligence obligations under the license agreement and what activities satisfy those diligence obligations;

●

the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and

●

the priority of invention of patented technology.

-35-

Table of Contents

In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed or sublicensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.

If we experience disruptions to our business relationships with our licensors, we could lose the ability to continue to source, develop and commercialize our product candidates, including ultimately losing our rights to such product candidates.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

~~-29-~~-36-

Table of Contents

ITEM 6. EXHIBITS

(b)

Exhibits


Exhibit No.		Description
3.1		Amended and Restated Certificate of Incorporation of First Wave BioPharma, Inc., as amended to date (incorporated by reference to Exhibit 3.1 of the Company’s Annual Report on Form 10-K filed with the SEC on March 20, 2023).
3.2		Amended and Restated Bylaws of First Wave BioPharma, Inc., as amended to date (incorporated by reference to Exhibit 3.2 of the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 15, 2022).
4.1		Form of ~~Inducement~~ Warrant (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed with the SEC on ~~June 16,~~July 18, 2023).
4.2		Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K filed with the SEC on July 18, 2022).
4.3		Form of Inducement Warrant (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed with the SEC on September 15, 2023).
4.4		Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed with the SEC on July 21, 2023).
4.5		Form of Warrant (incorporated by reference to Exhibit 4.2 of the Current Report on Form 8-K filed with the SEC on July 21, 2023).
10.1		Form of Purchase Agreement (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on July 18, 2023).
10.2		Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the SEC on July 18, 2023).
10.3		Form of Term Sheet (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on July 29, 2022).
10.4		License Agreement, dated September 13, 2023 (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on October 10, 2023).
10.5		Form of Purchase Agreement (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the SEC on July 21, 2023).
10.6		Form of Inducement Letter (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on ~~June 16,~~September 15, 2023)
~~10.2~~		~~Amendment to the 2020 Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on June 23, 2023)~~.
31.1*		Certification of the Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*		Certification of the Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**		Certification of the Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*		Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*		Inline XBRL Taxonomy Extension Schema Document
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document and included in Exhibit 101)

*filed herewith

**furnished, not filed

~~-30-~~-37-

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	FIRST WAVE BIOPHARMA, INC.

	By	/s/ James Sapirstein
		James Sapirstein
		President, Chief Executive Officer and Chairman
		(Principal Executive Officer)


	By	/s/ Sarah Romano
		Sarah Romano
		Chief Financial Officer
Date: ~~August 14,~~November 13, 2023		(Principal Financial and Accounting Officer)

~~-31-~~-38-


		Page

PART I. FINANCIAL INFORMATION

Item 1.	Unaudited Condensed Consolidated Financial Statements	13

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2327

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2833

Item 4.	Controls and Procedures	2833

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	2934

Item 1A.	Risk Factors	2934

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	2936

Item 3.	Defaults Upon Senior Securities	2936

Item 4.	Mine Safety Disclosures	2936

Item 5.	Other Information	2936

Item 6.	Exhibits	3037

SIGNATURES


	June 30, 2023	June 30, 2022
	(unaudited)	(unaudited)
Common stock warrants	5,520,575	59,233
Stock options	8,956	4,483
RSUs not yet issued	160,239	—
Convertible preferred stock (1)	3,157	3,416
Restricted stock not yet issued	162	162
Total shares of Common Stock issuable	5,693,089	67,294